When people hear the word “sauna,” many immediately think detoxification, relaxation, or a wellness luxury.

But for those of us carrying APOE4, sauna use may represent something far more important: a powerful hormetic intervention that supports vascular health, mitochondrial resilience, inflammation reduction, sleep quality and potentially dementia risk reduction.

After years of using an infrared sauna, I recently made the decision to replace it with a traditional Finnish-style sauna - the kind capable of reaching true high heat.

My new sauna arrives in July.

And the more deeply I reviewed the research, the more convinced I became that this was the right move.

The APOE4 Brain and Heat Stress

APOE4 brains appear to be uniquely vulnerable to:

• impaired glucose metabolism

• vascular dysfunction

• chronic inflammation

• mitochondrial stress

• reduced synaptic repair

• impaired clearance of metabolic waste

• reduced resilience to aging stressors

Many of the interventions that appear most beneficial for APOE4 carriers share one common feature:

They create a carefully controlled biological stress that forces the body to adapt and become more resilient.

Exercise. Fasting. Cold exposure. Hyperbaric oxygen. Resistance training. Heat.

Sauna belongs squarely in that category.

What the Research Actually Shows

Some of the strongest sauna data comes from Finland, where traditional high-heat sauna bathing is deeply embedded in the culture.

One of the landmark studies followed more than 2,000 middle-aged Finnish men over decades and found something remarkable:

Men who used a sauna 4–7 times per week had dramatically lower rates of dementia and Alzheimer’s disease compared to those using it only once weekly.

The reductions were substantial:

• lower dementia incidence

• lower Alzheimer’s incidence

• lower cardiovascular mortality

• lower all-cause mortality

This matters enormously for APOE4.

Why?

Because vascular dysfunction and impaired cerebral blood flow are increasingly recognized as central drivers of neurodegeneration.

And sauna appears to strongly influence vascular health.

Sauna Is Probably a Vascular Therapy as Much as a Heat Therapy

During a proper sauna session:

• heart rate rises significantly

• blood vessels dilate

• circulation improves

• endothelial function improves

• blood pressure often decreases afterward

• nitric oxide signaling increases

• cardiac output rises

Some researchers have even described traditional sauna bathing as producing cardiovascular effects similar to moderate exercise.

For APOE4 carriers - who often struggle with endothelial dysfunction and impaired cerebral perfusion decades before cognitive symptoms appear - this becomes highly relevant.

Heat Shock Proteins: The Cellular Repair Crew

One of the most fascinating mechanisms behind sauna therapy involves heat shock proteins.

These are highly conserved protective proteins produced when cells encounter stress.

Heat shock proteins help:

• refold damaged proteins

• stabilize mitochondria

• improve cellular resilience

• reduce oxidative stress

• support autophagy

• improve protein quality control

Protein misfolding is one of the hallmarks of neurodegenerative disease.

Anything that enhances cellular housekeeping becomes potentially important.

And high-heat sauna exposure appears to be one of the most potent natural inducers of heat shock proteins.

Why I Moved Away From Infrared

This is where things become controversial.

Infrared saunas are extremely popular in wellness circles.

They are marketed heavily for:

• detoxification

• convenience

• comfort

• easier heat tolerance

And to be fair, infrared saunas absolutely can induce sweating and mild heat stress.

But after digging through the literature, I became increasingly unconvinced that infrared reproduces the physiological intensity seen in the Finnish sauna studies.

The majority of the research showing reductions in dementia and cardiovascular mortality involved:

• traditional Finnish saunas

• very high ambient temperatures

• repeated cardiovascular challenge

• significant core temperature elevation

Many infrared saunas operate in the range of 120–140°F. (mine usually took 30 minutes to get to 130°F).

Traditional Finnish saunas commonly operate between 170–200°F.

That is not a small difference.

The physiological experience is entirely different.

A true Finnish sauna creates:

• far greater cardiovascular demand

• stronger vasodilation

• more profound heat shock protein activation

• higher heart rate elevation

• greater thermoregulatory adaptation

In many infrared saunas, users can comfortably sit for long periods while barely elevating cardiovascular output.

The “Sweet Spot” Appears to Be Repeated High-Heat Exposure

Based on both the Finnish data and mechanistic studies, the apparent sweet spot for brain and cardiovascular benefits seems to involve:

• temperatures roughly 170–190°F

• sessions around 15–25 minutes

• repeated exposure multiple times weekly

• enough heat to meaningfully elevate heart rate and core temperature

Frequency appears to matter.

The strongest protective associations in the Finnish data were seen in people using saunas 4–7 times weekly.

That does not mean everyone needs daily sauna use. But it does suggest that occasional casual use may not generate the same adaptations.

Sauna and Sleep

One of the most immediately noticeable benefits many people experience is improved sleep.

Paradoxically, raising body temperature before bed often improves the body’s later cooling response, which supports deeper sleep onset. I will wait to test that in July - as my infrared sauna usually kept me awake and gave me less restful sleep if I used it at night.

For APOE4 carriers, sleep quality matters enormously.

Deep sleep is when the brain’s glymphatic system becomes most active.

That is the system involved in metabolic waste clearance, including amyloid clearance.

Anything that reliably improves deep sleep may have downstream implications for long-term brain health. If better sleep holds true for me, I’ll report back once I have used my new sauna for a while.

Sauna Is Not a Free Pass

I do think sauna is a powerful tool. But it is not a magic bullet.

No one should imagine they can:

• ignore metabolic health

• remain sedentary

• eat a highly inflammatory diet

• neglect sleep

• ignore insulin resistance

• avoid strength training

…and then “sauna their way out” of APOE4 risk.

Sauna works best as part of a larger prevention-focused lifestyle.

It is one signal among many telling the body:

Adapt. Repair. Become more resilient.

Practical Considerations for APOE4 Carriers

If you are considering sauna use:

• Hydration matters.

• Electrolytes matter.

• Start slowly.

• Heat tolerance improves over time.

• Avoid pushing to dizziness or exhaustion.

• Be cautious with uncontrolled hypertension or cardiovascular instability.

And importantly:

The goal is not maximal suffering. It is repeated, tolerable adaptation.

Consistency likely matters more than heroic sessions.

Why I’m Excited About My New Sauna

On a recent trip to Paris, I used the Finnish sauna daily at our hotel. I noticed the difference in heat and since there was also a pool, I cooled off nicely after the sauna session. I felt wonderfully relaxed, yet invigorated afterwards.

My infrared sauna served a purpose. But ultimately, I now want the real thing:

• higher heat

• stronger cardiovascular conditioning

• more robust heat shock response

• a more authentic Finnish-style experience

Given everything we currently know about APOE4, vascular health, mitochondrial resilience, and hormesis, I suspect it may become one of the most valuable tools in my prevention toolbox.

Final Thoughts

If I had to summarize the sauna literature for APOE4 carriers, it would be this:

Heat - when applied intelligently and consistently - appears to train resilience across nearly every system APOE4 tends to stress.

The brain. The vasculature. The mitochondria. The inflammatory system. Sleep. That does not mean sauna is a cure, but it may very well be one of the most evolutionarily ancient and biologically coherent interventions we have.

And unlike many expensive therapies in longevity medicine, this one has thousands of years of human history behind it.

We spend a lot of time discussing what to eat, which supplements to take, which labs to track. And that conversation matters. But underneath all of it is an assumption that rarely gets examined - that we’re all working with roughly the same biological machinery, just with an APOE4 variant layered on top.

We’re not.

And for some of us, that difference is significant enough to fundamentally change what an effective protocol actually looks like.

I know this because I’ve spent years building mine - and the more I’ve learned about my own genetics, the more I’ve understood why certain interventions matter more for me than standard recommendations would suggest, and why some things that work for others may not work the same way for me.

Here’s what I mean.

The Compounding Genetic Stack

Most people in this community know their APOE status. Fewer know their MTHFR status. And almost nobody is talking about PEMT.

I carry all three:

• APOE4/4 - homozygous, two copies

• MTHFR C677T - homozygous, two copies

• PEMT rs7946 T/T - homozygous, two copies

Each one individually warrants a specialized approach. Together, they create a compounding vulnerability that sits at the intersection of lipid transport, methylation, and phosphatidylcholine synthesis - three systems that are deeply interconnected and all critically relevant to brain health.

Let me walk through what each one actually means, and why the interaction between them matters more than any single variant in isolation.

APOE4/4 - You Already Know This One

If you’re reading this, you’re likely familiar with what APOE4 does. It impairs cholesterol recycling and lipid transport, particularly in the brain. It reduces amyloid clearance efficiency. It increases neuroinflammatory vulnerability.

What’s less often discussed is that APOE4’s impact on lipid transport means your brain has a harder time getting the phospholipids it needs to maintain neuronal membranes, support synaptic function, and clear metabolic waste.

This isn’t just a cardiovascular story. It’s a membrane integrity story. And that matters for everything that follows.

MTHFR C677T Homozygous - The Methylation Bottleneck

The MTHFR enzyme converts folate into its active form (5-methyltetrahydrofolate) which feeds the methylation cycle and ultimately supports the production of SAMe, your body’s primary methyl donor.

C677T homozygous reduces this enzyme’s activity by approximately 70-80%.

The practical consequences:

• Synthetic folic acid - found in fortified foods and many supplements - doesn’t just fail to help. It actively competes with and blocks what little conversion capacity you have. It works against you.

• SAMe production is compromised, affecting dozens of methylation-dependent processes throughout the body

• Homocysteine tends to accumulate - and elevated homocysteine is directly neurotoxic, independently associated with cognitive decline, and particularly concerning in APOE4 carriers

For anyone with this variant, the form of B vitamins in your supplement stack isn’t a minor detail. It’s foundational. Methylfolate - not folic acid. Methylcobalamin - not cyanocobalamin. This distinction matters enormously and most generic B complexes and most multi-vitamin blends get it wrong.

PEMT rs7946 T/T - The Liver Connection Most People Miss

PEMT stands for Phosphatidylethanolamine N-Methyltransferase. It’s an enzyme responsible for one of the body’s pathways for synthesizing phosphatidylcholine - primarily in the liver.

The rs7946 T/T variant (also called G523A, ‘A’ allele) reduces PEMT activity by approximately 30% in laboratory assays. The primary documented consequence in research is increased risk of non-alcoholic fatty liver disease - specifically because reduced PC synthesis in the liver impairs the liver’s ability to shuttle fats out of hepatic cells efficiently, leading to fat accumulation.

A few important caveats:

• The 30% reduction has been measured outside the human body - in vivo human experiments haven’t yet confirmed the precise mechanism

• The negative effect appears diet-dependent - observed primarily in individuals consuming high calorie Western dietary patterns

• It has not been consistently observed across all populations studied

Why it’s still relevant to this conversation:

The liver is the primary site of PC production for systemic distribution. If hepatic PC synthesis is impaired - even partially - it plausibly affects phospholipid availability more broadly. This is mechanistically interesting in the context of APOE4’s already impaired lipid transport, but I want to be clear: this is a plausible connection, not a confirmed one.

What I can say with more confidence is that my dietary pattern - low sugar, Mediterranean-leaning, lean body composition - is essentially the opposite of the high calorie Western diet that appears to trigger the negative PEMT expression. My liver enzymes are normal and triglycerides are low, suggesting this variant isn’t expressing negatively in my current context.

The practical implication I draw from carrying this variant - alongside the APOE4 and C677T combination - is that supporting PC availability through direct supplementation and dietary sources makes mechanistic sense as a precautionary measure. BodyBio PC, egg yolks, and choline-rich foods aren’t just generally good APOE4 choices. For someone with my genetic profile, they feel specifically warranted.

But I share this with appropriate humility - the science here is preliminary, and I’d encourage you to evaluate it accordingly rather than treating it as established fact.

What This Means Practically

Here’s what it means for my protocol specifically - shared not as prescription but as illustration of the principle:

BodyBio PC has become non-negotiable for me. Not just helpful - essential. Given impaired PEMT function, my endogenous phosphatidylcholine synthesis capacity may be less efficient. Delivering it directly via phospholipid complex bypasses the reduced efficiency pathway entirely. My Prodrome scan data shows this working - Total Phosphatidylcholines jumped from the 13th to 43rd percentile between annual scans following consistent PC supplementation.

Egg yolks matter more than standard recommendations suggest. Dietary phosphatidylcholine from egg yolks partially bypasses PEMT by delivering preformed PC directly. This isn’t about cholesterol anxiety - it’s about membrane substrate delivery. For me, three to four yolks daily feels biologically justified by this specific genetic context.

Methylated B vitamins are non-negotiable. Thorne Basic B or equivalent using 5-MTHF methylfolate and methylcobalamin. I personally avoid folic acid. Auditing every supplement in your stack for synthetic folic acid matters.

TMG (Trimethylglycine) supports both impaired pathways simultaneously. It provides an alternative methylation route that bypasses the impaired MTHFR enzyme, supporting homocysteine clearance and partially restoring methyl donor availability for whatever residual PEMT activity remains.

Homocysteine tracking becomes a primary biomarker. Not an afterthought. The C677T and PEMT combination creates compounding pressure on homocysteine elevation. Getting it below 7 and ideally toward 6 µmol/L is a meaningful target with direct neuroprotective implications.

Importantly, PEMT is not the body’s only phosphatidylcholine synthesis pathway. The CDP-choline (Kennedy) pathway also contributes significantly, but reduced PEMT efficiency may still increase reliance on dietary choline and preformed phosphatidylcholine.

The Bigger Point

Generic APOE4 protocols are built for the average APOE4 carrier. They’re useful starting points. But the APOE4 community is not genetically homogeneous, and the assumption that one protocol fits all is the same oversimplification we rightly criticize in mainstream medicine’s one-size-fits-all approach.

Knowing your APOE status is the beginning of personalization, not the end of it.

If you haven’t looked at MTHFR status, PEMT rs7946 or your phytosterol absorption genetics - and you’re finding that standard APOE4 protocols aren’t moving your biomarkers the way you’d expect - these variants are worth investigating.

Not to induce more anxiety. But because knowledge of the actual biological terrain you’re working with allows you to build something precise rather than generic.

The goal isn’t to follow someone else’s protocol. The goal is to understand your own biology deeply enough - it goes well beyond the APOE gene - to build one that actually fits.

That’s what I’m working on. And these three variants - APOE4/4, C677T, PEMT T/T — are a significant part of why my protocol looks the way it does.

As always - this is what I do and why. Not medical advice. Take it to your clinician, your functional medicine practitioner, or your own research process. The point is to give you better questions, not ready-made answers.

If you’ve tested for PEMT or MTHFR and found similar results, I’d love to hear about it in the comments. This is exactly the kind of community knowledge that helps all of us build more precise protocols.

Related resources worth exploring:

• Goodenowe’s plasmalogen research and ProdromeScan for phospholipid biomarker tracking

• Bredesen PreCODE framework for comprehensive APOE4 protocol building

• Husseine Yassine’s DHA transport research in APOE4 carriers

• MTHFR specific resources from Ben Lynch’s Dirty Genes framework

And then the obvious question hit me: if beneficial compounds get in that easily... what else does?

The Back Door to the Brain

Most people have heard of the blood-brain barrier (BBB) - that remarkable biological security system that keeps harmful substances out of your brain. We take comfort in it. We assume it’s doing its job.

What we’re rarely told is that there’s an unsecured back door.

The olfactory nerve runs directly from the nasal epithelium straight into brain tissue. It doesn’t cross the BBB. It bypasses it completely. This pathway - called the olfactory-trigeminal route - allows substances to travel via:

• Transcellular transport - through nerve cells themselves

• Axonal transport - riding along nerve fibers directly into the brain

• Paracellular transport - slipping between cells along the nerve

This is why intranasal drug delivery is so promising for neurological conditions. Researchers are using this pathway to deliver Alzheimer’s treatments, peptides, and hormones directly to brain tissue without the usual barriers.

But here’s what is largely ignored: the brain doesn’t distinguish between a therapeutic peptide and a toxic fume. The door doesn’t check credentials. It just opens.

The Workers Nobody Is Warning

When I sat with this idea, my mind immediately went to the people who spend eight hours a day, five days a week, breathing in chemicals that most of us encounter only occasionally - if ever.

Hairdressers and salon workers live inside a chemical cocktail. Hairspray, keratin treatments, hair relaxers, permanent wave solutions, and bleaching agents fill the air of salons daily. Formaldehyde - a known carcinogen and neurotoxin - is a primary ingredient in many keratin smoothing treatments. The women who perform these services often work in poorly ventilated spaces, breathing it in for hours on end, for entire careers. Most are never told what that means for their brain.

Nail technicians face a particularly insidious mix. Acrylic monomers, acetone, UV gel chemicals, and adhesive solvents create a persistent chemical haze in nail salons. Studies have found significantly elevated levels of volatile organic compounds (VOCs) in nail salon air - many of which are known neurotoxins. Ventilation is often inadequate. Many nail technicians are immigrant women who may face additional barriers to accessing health information or advocating for safer working conditions.

Welders and machinists have one of the most well-documented occupational neurotoxin exposures of any profession. Manganese fumes — produced during welding - are so consistently linked to Parkinson’s-like neurological damage that the condition has its own name: manganism. The olfactory-nasal pathway is believed to be a primary route by which manganese reaches the brain. Yet welding remains one of the most common trades in the world, often performed with minimal respiratory protection.

Painters and auto body workers breathe solvents - toluene, xylene, isocyanates - that are fat-soluble, meaning they readily cross into neural tissue. Long-term solvent exposure is associated with cognitive decline, memory impairment, and mood disorders, a constellation sometimes called painters’ syndrome in occupational health literature.

Dry cleaning workers spend their days with perchloroethylene (PERC), a chlorinated solvent classified as a probable human carcinogen. PERC is also a neurotoxin with documented links to cognitive decline and Parkinson’s disease risk with long-term exposure.

Farmers and agricultural workers face pesticide drift - chemicals that were designed to affect the nervous systems of insects don’t stop at species boundaries. Organophosphate pesticides in particular have been linked to neurological damage in farmworkers, and chronic low-level inhalation via the olfactory pathway is an area of growing research concern.

Embalmers and funeral workers work with formaldehyde daily, for entire careers. This is one of the highest-exposure occupational groups for a compound with both carcinogenic and neurotoxic properties, yet it receives almost no public health attention.

Firefighters deserve a category of their own. Structure fires produce a toxic soup of combustion byproducts - benzene, hydrogen cyanide, acrolein, heavy metals from burning electronics - that firefighters inhale repeatedly throughout their careers. The neurological consequences are increasingly being studied, and the findings are not reassuring.

It’s Not Just What You Breathe

The story gets broader when you realize the nasal pathway isn’t the only backdoor.

Cashiers handle receipt paper dozens to hundreds of times per shift, every working day. What most people don’t know is that about 80% of thermal receipt paper is coated in free BPS (Bisphenol-S, a chemical cousin of BPA) not bound into plastic like in water bottles, but sitting on the surface, ready to absorb through skin on contact. Studies have found that cashiers carry significantly higher Bisphenol levels in their urine than the general population. Bisphenols are endocrine disruptors that mimic estrogen, disrupting hormonal systems, thyroid function, and metabolic health. The health implications are well known and conscientious corporations are moving to phasing out use of receipt paper containing Bisphenol. Receipts from Best Buy, Costco, CVS, H&M, Starbucks, and Target were among those that didn't contain Bisphenols in recent testing.

Here’s the detail that makes it worse: using hand sanitizer before handling receipts dramatically increases Bisphenol absorption. The alcohol in sanitizer increases skin permeability, essentially opening the door wider. Well-meaning hygiene habits, making things worse.

Bank tellers handle currency all day - currency that itself picks up Bisphenol from contact with receipts throughout its circulation. Bartenders and servers handle printed tickets all shift while also working with alcohol-based cleaning products that increase their skin’s absorptive capacity. These are not exotic industrial workers. These are people working in every town, every city, in jobs that nobody associates with toxic exposure.

The Alzheimer’s and Parkinson’s Connection

This is where the research gets both fascinating and deeply troubling.

The olfactory bulb - the first brain structure substances reach via the nasal pathway - is also one of the first brain regions to show damage in both Alzheimer’s and Parkinson’s disease. The loss of smell is now recognized as an early warning sign of both conditions, often appearing years before other symptoms.

This is probably not a coincidence.

Some researchers now believe that chronic low-level nasal exposure to environmental toxins may be a significant and under-appreciated driver of neurodegenerative disease. The nose offers a relatively unguarded route of entry, repeated exposures accumulate over decades, and the first casualties - the olfactory neurons - are the very cells whose death we’re now recognizing as an early marker of neurodegeneration.

Ultrafine air pollution particles - produced by vehicle exhaust and combustion — have been physically found in human brain tissue. Urban residents who live near high-traffic areas show higher rates of cognitive decline. Children in heavily polluted cities show measurable differences in brain development.

The picture that emerges is one where the brain is far less protected from its environment than we have assumed - and where the people carrying the greatest burden of that exposure are often the least able to do anything about it.

What This Means Practically

For most people, complete avoidance isn’t realistic. But awareness changes behavior, and behavior changes outcomes.

Ventilation is neurological protection. This isn’t just about lungs. Opening windows, running exhaust fans, and working in well-ventilated spaces reduces the concentration of airborne compounds reaching the olfactory nerve. For salon and workshop owners, this is a moral obligation as much as a practical one.

N95 masks filter particles more effectively than surgical masks. For anyone in high-exposure occupational settings, the difference matters - not just for lungs but for what reaches the brain.

Nitrile gloves when handling receipts significantly reduce BPA skin absorption. This is a cheap, easy intervention that virtually no cashier has been told about.

Nasal saline rinses are being studied as a way to clear particulates before absorption occurs. The evidence is still emerging, but the mechanism is plausible and the risk is essentially zero.

The hand sanitizer and receipt combination is worth specifically knowing about - the interaction isn’t intuitive, but it’s documented. Wash hands after handling receipts rather than sanitizing before.

A Quiet Injustice

There is something worth sitting with here beyond the science.

The people with the highest occupational exposures to neurotoxic compounds are, disproportionately, people in lower-wage service jobs - nail technicians, cashiers, hairdressers, agricultural workers, cleaners. They are making other people look beautiful, keeping stores running, growing food. They are often working in conditions they didn’t choose, with information they are never given.

The research on occupational neurotoxin exposure exists. The mechanisms are increasingly understood. But the distance between what researchers know and what a nail technician in a strip mall salon knows is vast - and that distance has consequences that play out over decades, quietly, in the form of cognitive changes and neurological disease that nobody connects back to the air she breathed for thirty years.

Understanding how the body’s defenses actually work - and where they don’t - is a first step toward changing that.

The earliest stages are also the most treatable.

Decline is not inevitable. The trajectory can be bent - sometimes dramatically - when the right systems are targeted early and consistently.

One of the most inspiring examples of this is Judy Benjamin, diagnosed with Alzheimer’s 13 years ago, who recently completed a 3,000-mile walk across the United States at age 81 to raise awareness for prevention. Judy is often described as Dale Bredesen’s “Patient Zero,” having implemented his RECODE protocol as outlined in Dr. Bredesen’s book, “The End of Alzheimer’s”.

Judy’s story isn’t a miracle. It’s a roadmap.

Early, aggressive, multi-system intervention can preserve function for years -sometimes more than a decade. And that’s especially true for APOE4 carriers.

Why Early Intervention Matters

Alzheimer’s doesn’t begin with memory loss. It begins silently, years earlier, with:

• Glucose hypometabolism

• Mitochondrial dysfunction

• Synapse loss

• Chronic neuroinflammation

• Sleep disruption

• Lipid and membrane breakdown

The earlier you interrupt these cascades, the more brain you preserve.

My 15 Most Important Staples for Early Alzheimer’s Prevention

I’m not waiting for a diagnosis. I’ve been implementing extensive prevention strategies in my daily life since finding out my APOE4/4 status years ago.

These are the interventions with the strongest human data, the most compelling biology, and the best real-world results, particularly for APOE4 carriers.

1. Fix Metabolism, Insulin Resistance, and Gut Health (the #1 lever)

Brain energy failure appears years before symptoms.

Targets:

• Fasting glucose: 75–85 mg/dL

• A1C: ≤ 5.2

• Fasting insulin: < 4

• Microbiome testing and correction

Metabolic repair stabilizes cognition better than almost any drug.

2. High-Dose DHA (2–3 g/day, APOE4-aware) and PC

APOE4 brains struggle to transport DHA across the blood–brain barrier.

High-DHA intake (especially DHA-PC) supports:

• Synapse repair

• Reduced neuroinflammation

• Slower hippocampal atrophy

PC supports:

• Synaptic membranes

• DHA delivery

• Neurotransmission

• Lipid balance

PC + DHA is one of the most effective synaptic repair combinations. I eat SMASH fish (Sardines, Mackerel, Anchovies, Salmon, Herring) at least 4 times a week, which is a more effective delivery of phospholipid DHA to the brain than taking a supplement! (I skip the anchovies because I don’t like their salty taste).

3. Plasmalogens (Neuro + Glia)

Plasmalogens drop early in Alzheimer’s. Supplementation has been shown to:

• Improve memory

• Increase cognitive scores

• Support synaptic integrity

I’ve used plasmalogens for years. They aren’t cheap - but neither is cognitive decline. Studies show that those with the highest brain plasmalogens have the lowest incidence of dementia.

4. Lower Homocysteine (< 7 µmol/L)

High homocysteine predicts brain atrophy and faster decline - yet is rarely tested.

Lowering it slows progression in randomized trials.

Key tools:

• Methyl or hydroxy-B12 (injections early on)

• Methylated folate

• TMG (trimethylglycine)

Nearly half the population carries an MTHFR gene variant and doesn’t know it. It can negatively impact methylation - a vital process for DNA, neurotransmitters and detoxification.

5. Repair Sleep Architecture (Critical for APOE4)

Sleep is when the brain clears amyloid and tau.

Foundational supports:

• Melatonin (≥ 2–3 mg; I personally use higher doses)

• Glycine, magnesium, L-theanine

• Evening red light

• Consistent bedtime

• Eliminate alcohol - it obliterates deep sleep!

6. Reduce Neuroinflammation (Microglial Control)

Chronic inflammation accelerates decline.

Helpful tools include:

• DHA

• Curcumin

• Optimized vitamin D

• Polyphenols

• Melatonin

• Low-dose aspirin (if appropriate)

• Low-dose naltrexone (LDN) to reduce hs-CRP … this addition to my stack made a marked improvement in my hs-CRP - now usually below 0.5!

7. Mild Ketosis (APOE4-Friendly)

Ketones bypass glucose failure and fuel neurons directly.

My Goal: mild, not extreme ketosis

• Low-glycemic diet

• 12–14 hour overnight fast

• C8 MCT powder (better lipid profile for APOE4). While I am not on a ketogenic diet due to my slender build and having no weight to lose, I add C8 MCT Powder to my morning coffee and I am generally in mild ketosis in the hours before noon. (0.5 – 2 mmol/L)

8. Lithium (Low-Dose, Neuroprotective)

Lithium is one of the most underappreciated neuroprotective tools available.

Low-dose lithium:

• Inhibits GSK-3β (tau phosphorylation)

• Enhances autophagy

• Supports mitochondrial resilience

• Is associated with lower dementia rates in epidemiologic studies

This is not psychiatric-dose lithium and generally has no noticeable side effects.

9. NAD⁺ Support (Cellular Energy & Repair)

NAD⁺ declines with age and is critical for:

• Mitochondrial function

• DNA repair

• Sirtuin activation

• Neuronal survival

Support options include:

• NMN or NR

• NAD⁺ injections or infusions (advanced)

• Exercise and fasting (foundational)

Energy failure is an early Alzheimer’s event - NAD directly addresses it.

10. Daily Exercise — Non-Negotiable

Exercise raises BDNF and slows progression.

AD-optimized formula:

• Zone 2: 45 min, 5–6×/week

• Strength training: 3×/week

• Steps: 10,000–12,000/day

I do 20 minutes of weight training every other day. Usually two sets (12 repetitions) of 5-6 exercises. Minimum 3 times a week I add a 45 minute Nordic Walking hike through a peaceful woodland preserve in my neighborhood. In addition, I use my rebounder daily, usually enjoying two 15 minute sessions of jumping to my favorite music!

11. Thyroid Optimization (Especially T3)

Low thyroid function - especially low T3 - accelerates decline.

Targets:

• Free T3: upper third of range

• Reverse T3: low. (I’ve fine-tuned mine to <11)

Cellular hypothyroidism = cognitive vulnerability. If you’re on Levothyroxine replacement therapy, please check out my previous post on the topic!

12. Red / Near-Infrared Light (Photobiomodulation)

Supports:

• Mitochondrial ATP

• Cerebral blood flow

• Neuronal repair

• Sleep quality

• Reduced inflammation

Often used alongside metabolic and exercise therapy in long-term success cases. I use redlight therapy daily and believe it’s a non-negotiable addition to brain protection.

13. Melatonin (Neuroprotective Doses)

Melatonin:

• Reduces oxidative stress

• Stabilizes mitochondria

• Modulates protein phase separation

• Reduces tau and amyloid toxicity

For APOE4 carriers, melatonin is profoundly protective.

14. HBOT (Hyperbaric Oxygen Therapy)

HBOT is one of the most promising non-pharmacologic interventions for early cognitive decline.

Emerging human data show improvements in:

• Cerebral blood flow

• Mitochondrial function

• Processing speed and memory

• Neuroinflammation

• Sleep and overall energy

By increasing dissolved oxygen in plasma, HBOT enhances mitochondrial ATP production, supports angiogenesis, and improves tissue repair - all critical in a brain suffering from hypometabolism.

If accessible, HBOT is a high-leverage investment early in the disease process.
I personally invested in my own chamber in 2025 and noticed meaningful improvements in energy, drive, and overall well-being within the first few weeks.

15. Rapamycin (Intermittent, Carefully Dosed)

Rapamycin targets one of the core drivers of neurodegeneration: chronic mTOR overactivation.

When used intermittently and at low doses, rapamycin may:

• Enhance autophagy (clear damaged proteins and organelles)

• Reduce neuroinflammation

• Improve mitochondrial efficiency

• Support vascular and immune health

Importantly, this is not daily immunosuppression. In longevity and neuroprotection contexts, rapamycin is pulsed, with careful attention to dose, timing, and individual response.

I’ve been taking once weekly rapamycin since 2021. With occasional breaks to wash out any residual buildup, I believe it’s an easy strategy for anyone past reproductive years carrying the APOE4 gene to protect the blood-brain barrier integrity.

The Takeaway

You cannot “cure” Alzheimer’s - but you can implement a thoughtful prevention strategy and, especially when addressed early, potentially change its trajectory. Dale Bredesen’s books The End of Alzheimer's and The End of Alzheimer's Program offer an invaluable roadmap for anyone concerned about Alzheimer’s disease - whether for themselves or a loved one.

Judy Benjamin’s 3,000-mile walk sends a clear message to everyone:

You are not powerless.
Your brain is not doomed.
Your choices matter.

Disclaimer

This article reflects my personal research, experience, and health practices and is shared for educational and informational purposes only. It is not medical advice and should not be used to diagnose, treat, or replace guidance from a qualified healthcare professional.

Many of the interventions discussed - including supplements, peptides, off-label medications, hyperbaric oxygen therapy, and lifestyle strategies - may not be appropriate for everyone and can carry risks depending on individual health status, genetics, and medications. Decisions about medical treatment should always be made in consultation with a knowledgeable physician.

Alzheimer’s disease and cognitive decline are complex, multifactorial conditions. While early, multi-system intervention may improve outcomes or slow progression, no intervention discussed here is presented as a cure.

If you are new here: APOE status is determined primarily by two SNPs (genetic markers): rs429358 and rs7412. In most direct-to-consumer genetic reports, APOE4/4 corresponds to rs429358 C/C and rs7412 C/C.

But upstream, there’s a potential failure in the making - one that doesn’t get nearly enough attention.

It starts in the mitochondria.

More specifically, it starts with something called cardiolipin.

Cardiolipin is a specialized fat found almost exclusively in the inner membrane of our mitochondria. It’s not just structural - it’s essential. It holds the entire energy-producing system together. Without it, the machinery that generates ATP begins to falter.

And here’s where it could be relevant - and especially for APOE4 carriers.

As we age, cardiolipin becomes damaged and oxidized. In Alzheimer’s brains, this process is significantly accelerated. The result is a gradual breakdown in mitochondrial efficiency: less energy, more oxidative stress, and increasingly vulnerable neurons.

In other words, before there are plaques… there is an energy problem.

APOE4 appears to amplify this vulnerability. Increased oxidative stress and altered lipid handling make it harder to maintain membrane integrity - including cardiolipin. Over time, this may potentially contribute to the metabolic fragility we see in the APOE4 brain.

So the question becomes:

Can we stabilize the system before damage becomes irreversible?

That’s what led me to SS-31 (Elamipretide).

SS-31 is a small peptide that targets the mitochondria directly. It binds to cardiolipin and helps stabilize the inner membrane, improving efficiency of the electron transport chain and reducing oxidative stress.

It doesn’t address amyloid.
It doesn’t target tau.

It supports something more fundamental: the cell’s ability to produce energy cleanly and efficiently.

In animal models, SS-31 has been shown to:
• Improve mitochondrial function
• Reduce oxidative damage
• Support synaptic health
• Improve cognitive performance

Human data - honestly - is very limited, and this is definitely not a mainstream intervention. But mechanistically, I find it compelling - especially when I’m thinking of ways to maintain my brain until the proverbial “fat lady” sings.

For that reason - and in consideration of my risk that compounds continuously with age (and particularly in the 8th decade of life!) - I decided to incorporate SS-31 into my protocol. Not continuously - but in cycles.

My goal is not constant stimulation, but periodic support - giving mitochondria a chance to repair and reset.

This fits into my broader strategy:
• Maintaining metabolic flexibility
• Supporting mitochondrial biogenesis (exercise)
• Providing membrane building blocks (DHA, phospholipids)
• Reducing oxidative stress

SS-31 is simply one piece of that puzzle.

As always, this is not medical advice - just a reflection of how I’m thinking about prevention, based on current science and personal exploration.

But if there’s one takeaway, it’s this:

We shouldn’t wait for visible pathology to start supporting the systems that keep our neurons alive. And at 73, I certainly don’t have the luxury of time on my side - to wait for science to catch up.

Sometimes the most important interventions are the ones that protect what we can’t see and I’m absolutely willing to take calculated risks when it comes to protecting and preserving the most important part of my body - my brain.

For those interested in diving a little deeper, here is more on the mechanistic picture of SS-31:

1. It stabilizes cardiolipin structure (prevents distortion)

Cardiolipin is uniquely shaped (4 fatty acid tails), which makes it fragile, especially under oxidative stress.

SS-31:

• Inserts itself along cardiolipin-rich regions of the inner mitochondrial membrane

• Prevents cardiolipin from becoming disorganized or “floppy”

2. It protects cardiolipin from peroxidation

Cardiolipin is extremely vulnerable to oxidation (especially its DHA-rich forms).

SS-31:

• Reduces reactive oxygen species (ROS)–induced peroxidation

• Interrupts the cycle where damaged mitochondria → more ROS → more cardiolipin damage

Key effect:

• Preserves functional (non-oxidized) cardiolipin pools

3. It restores electron transport chain supercomplexes

This is one of the most important (and underappreciated) effects.

Cardiolipin is required to assemble:

• Complex I, III, IV into supercomplexes (“respirasomes”)

SS-31:

• Helps cardiolipin maintain the proper curvature and charge environment

• Re-forms and stabilizes these supercomplexes

Result:

• More efficient electron flow

• Less electron “leak” → less ROS

4. It improves cytochrome c function (without triggering apoptosis)

Normally:

• Cardiolipin anchors cytochrome c to the inner membrane

When cardiolipin gets oxidized:

• Cytochrome c detaches → triggers apoptosis cascade

SS-31:

• Maintains cardiolipin in a reduced (healthy) state

• Keeps cytochrome c functionally engaged in energy production, not cell death signaling

Subtle but powerful:

• Supports ATP production

• Reduces inappropriate apoptosis signaling

5. It improves mitochondrial membrane curvature & cristae integrity

Cardiolipin shapes:

• The folds (cristae) inside mitochondria

SS-31:

• Preserves proper membrane curvature

• Prevents cristae collapse or fragmentation

6. It decouples ROS production from ATP generation

In damaged mitochondria:

• ATP production ↓

• ROS ↑

SS-31 helps:

• Restore efficient coupling

• So mitochondria can produce ATP without excessive oxidative spillover

7. It may facilitate cardiolipin remodeling indirectly

Cardiolipin undergoes constant remodeling (via enzymes like tafazzin).

While SS-31 doesn’t directly remodel:

• By protecting cardiolipin from oxidation

• It preserves substrates needed for proper remodeling cycles

Bottom line (what it’s really doing)

SS-31 doesn’t just “bind cardiolipin”, it:

• Preserves its structure

• Prevents its oxidation

• Keeps cytochrome c in energy mode (not death mode)

• Stabilizes mitochondrial ultrastructure

• Restores efficient ATP production

Pain. Fatigue. Brain fog. A racing heart.

But blood pressure?
It’s silent - while exerting a constant mechanical force on one of the most delicate systems in the body: our brain.

From My Own Experience

I’ve seen this play out personally.

There was a time when I was taking T4-only thyroid medication, and my thyroid labs looked acceptable.

But my blood pressure told a different story - it was consistently registering a bit elevated and gradually increasing, without any obvious reason.

Diet hadn’t changed. Lifestyle hadn’t changed. It wasn’t until I threw out the T4 meds in 1999/2000 - and addressed my continuing sub-clinical hypothyroid state - that my blood pressure gradually returned to a solid baseline under 120/80.

That connection stayed with me.

Why Blood Pressure Matters

Our brain is not just an organ - it’s a dense network of microscopic vessels delivering oxygen, glucose, and nutrients with extraordinary precision.

Now imagine those vessels under constant pressure.

Not enough to trigger symptoms.
Not enough to send us to the doctor.
But just enough - over years - to cause subtle damage.

The resulting damage is:

• Micro-tears in vessel walls

• Reduced elasticity

• Impaired blood flow

• Breakdown of the blood-brain barrier

Over time, this can translate into:

• Reduced cognitive resilience

• Increased risk of vascular dementia

• Greater vulnerability to Alzheimer’s pathology

“I feel fine” doesn’t mean much here

One of the most misleading assumptions is that if blood pressure were a problem… you’d know it.

You wouldn’t.

Elevated blood pressure is often completely asymptomatic - even when it’s doing real damage.

And there is nuance:

• A “normal” reading at the doctor’s office doesn’t tell the full story

• Spikes during stress, poor sleep, or exertion often go unnoticed

• Nighttime blood pressure (when our brain is repairing itself) may be the most important - and the least measured

We can feel great… and still be quietly accumulating risk.

What This Means for APOE4 Carriers (and Anyone Who Cares About Their Brain)

To protect our cognitive future - blood pressure becomes important and a marker we want to understand clearly!

Why?

Because it amplifies everything else.

• Inflammation becomes more damaging

• Lipid transport issues become more consequential

• Microvascular dysfunction accelerates

It’s not just a number. It’s a damage multiplier.

Subtle Signs Something May Be Off

We may not “feel” high blood pressure - but our bodies sometimes give us subtle cues.

• Poor sleep quality or frequent nighttime waking

• Feeling wired but tired

• Head pressure (not pain - just pressure)

• Reduced exercise tolerance

• Increased heart rate variability instability

While these symptoms aren’t diagnostic - they’re clues worth paying attention to.

What to do (Without Overcomplicating It)

1. Measure - Don’t Assume

• Take your blood pressure at home

• Measure at different times (morning, evening, post-exercise)

• Pay attention to patterns - not just isolated readings

2. Hydration Matters

Even mild dehydration can elevate blood pressure.

• Start your day hydrated

• Maintain steady fluid intake - not just when thirsty

3. Vascular System Training

Our blood vessels respond to how we use them.

• Regular walking

• Resistance training

• Short bursts of higher intensity (as tolerated)

This is more than just fitness - it’s vascular conditioning.

4. Sleep Is a Blood Pressure Event

If your sleep is fragmented, your blood pressure likely is too.

• Prioritize consistent sleep timing

• Reduce late-night stimulation

• Pay attention to nighttime awakenings

5. Manage the “Invisible Load”

Stress doesn’t just affect your mind - it affects your pressure.

• Breathing practices

• Time outdoors

• Deliberate downshifting during the day

The Takeaway

Since we are building a plan for long-term brain health, we can’t overlook the quiet forces.

They’re often the ones that matter most. I used to assume my blood pressure was great. Now, I verify! Periodically I track pressure for several weeks at a time - several times a day - consistently at the same time.

That naturally raises the next question:

If this biology is real, how do we know whether it’s being pushed, or kept relatively quiet, in our own bodies?

We don’t yet have clinical tests that show lipid droplets in astrocytes or APOE lipidation in the brain. But we do have something useful: advanced lipoprotein panels that offer indirect signals about how hard the lipid system is being asked to work.

These markers are good context, and for APOE4 carriers, context matters.

A quick framing (important)

This post is not about chasing perfect numbers or defining universal targets.

What follows are the markers I personally watch, and the directional ranges that give me confidence that my APOE4 biology is operating in a relatively calm environment.

This is not a prescription.
It is how I translate mechanism into monitoring with available information I can get.

The markers I pay closest attention to

1. VLDL & VLDL-P

VLDL reflects triglyceride-rich particle flux and inflammatory lipid signaling, a burden APOE4 is less equipped to manage.

What I look for

• Low and stable VLDL

• No upward drift over time

• No post-meal or fasting spikes

For me, lower VLDL suggests a quieter peripheral lipid environment and less downstream stress on fragile lipid-handling pathways.

2. Remnant lipoproteins (one of the most important signals for me)

Remnant lipoproteins are highly inflammatory and APOE-dependent for clearance. When elevated, they are associated with endothelial dysfunction and increased inflammatory signaling.

What I aim for

• Remnant lipoproteins firmly in the low range

• Consistency over time, not one-off lows

Low remnants suggest that APOE4 is not being repeatedly activated to clear lipid debris in a hostile metabolic environment - a situation where it behaves worst.

3. Triglycerides

Why they matter

Triglycerides themselves are not inherently toxic. Chronically elevated levels, however, reflect impaired lipid utilization and increased remnant production - both of which amplify APOE4 stress.

What I look for

• Low fasting triglycerides

• Minimal variability

4. LDL-P and LDL-C (with perspective)

LDL often dominates lipid discussions, but I view it as context, not the primary signal.

• Particle number matters

• But metabolic environment matters more

• LDL is rarely the first system to fail in APOE4 biology

5. ApoB (with context)

ApoB reflects the total number of atherogenic particles circulating in the blood. Each LDL, VLDL remnant, and IDL particle carries one ApoB molecule.

For APOE4 carriers, ApoB provides a useful summary of particle burden, but it does not tell the whole story.

How I interpret it

• ApoB tells me how many particles are present

• It does not tell me how inflammatory, triglyceride-rich, or metabolically stressful those particles are

• It does not reflect lipid trafficking efficiency inside the brain
  
  When ApoB is low and remnants, VLDL, and triglycerides are low, that combination is reassuring.
  When ApoB is low but remnants are high, I care far more about the remnants.

6. ApoA1 (supporting capacity, not a shield)

ApoA1 is the main structural protein of HDL and reflects the body’s capacity for reverse cholesterol transport and lipid recycling.

• ApoA1 provides information about transport capacity

• Higher is not always better

• Function matters more than quantity

I monitor ApoA1 as a supporting signal, not as a guarantee of protection. Favorable ApoA1 does not override inflammatory lipid flux, poor metabolic control, or impaired lipid utilization.

7. Omega-3 Index (membrane resilience, not a nutrient checkbox)

The Omega-3 Index reflects the percentage of EPA and DHA incorporated into red blood cell membranes, serving as a proxy for long-term membrane composition and stability.

For APOE4 carriers, this marker is particularly relevant because APOE4 biology places chronic stress on lipid membranes, mitochondrial function, and glial support systems - all areas where DHA plays a foundational structural role.

Omega-3 Index is not simply a dietary or cardiovascular marker. It is a membrane quality signal.

It reflects how resilient cell membranes are in the face of oxidative stress, inflammatory signaling, and metabolic strain - conditions under which APOE4 tends to perform worst.

Low Omega-3 Index suggests membranes that are more rigid, more vulnerable to peroxidation, and less able to buffer lipid-related stress. For APOE4 carriers, that fragility matters.

What I look for

• Omega-3 Index in a robust, stable range (9%+)

• Consistency over time rather than episodic highs

• Alignment with low triglycerides, low remnant lipoproteins, and low inflammatory markers

A favorable Omega-3 Index does not override poor metabolic control or inflammatory lipid flux. But when it is adequate and stable - alongside quiet lipid signaling - it supports a more resilient, less reactive membrane environment.

8. HDL markers (with restraint)

HDL quantity does not equal HDL function.

Very low HDL-P can suggest reduced lipid recycling capacity, but HDL metrics are blunt tools. I view them as supporting indicators, not decision drivers.

9. Lp(a): context, not control

Lp(a) is genetically determined and largely non-modifiable. I track it for vascular awareness, but I don’t confuse it with lipid trafficking failure or neurodegenerative risk. I am one of the +/- 25% of the population who carries elevated lp(a). If you haven’t been tested for this highly atherogenic lipoprotein, don’t delay. It should be checked at least once. Levels usually remain fairly stable throughout life since elevated levels are genetic.

My personal “directional targets”

Again, these are not universal goals. They are the ranges that, I believe in my case, suggest a quieter lipid environment for APOE4 biology.

• Triglycerides: low and stable

• VLDL / VLDL-P: low

• Remnant lipoproteins: low

• LDL-P: interpreted in context, not isolation

• hs-CRP: low

• Fasting insulin: low

• Glycemic variability: minimal

• Sleep: deep, continuous, and protected

What these markers cannot tell me (and I’m clear about this)

Advanced lipid panels:

• Do not measure brain APOE directly

• Do not show glial lipid droplets

• Do not guarantee protection

  What they do tell me is whether the background metabolic environment is likely to amplify or dampen APOE4-related stress.

Quieting the system vs chasing numbers

My goal is:

• Reduced inflammatory lipid flux

• Less clearance burden

• Stable metabolic signaling

• Fewer repeated stress cycles

In other words: a quieter system that allows fragile lipid-handling pathways to keep up over time.

The bigger picture

Advanced lipoprotein panels don’t replace imaging or future molecular tools. But today, they are among the best accessible ways to infer whether APOE4 biology is being chronically challenged - or given room to function.

Combined with upstream strategies like membrane support, lipid replacement, metabolic stability, and sleep protection, these markers help me course-correct and give me a sense of control.

The takeaway

For me, learning how to read lipoprotein signals through an APOE4 lens has shifted prevention from fear-based interpretation to informed, systems-level monitoring.

Not certainty, but clarity.

And clarity is what facilitates calculated, common sense strategy that will hopefully retain my cognition and memory until that last breath.

For years, I did what many health-conscious people do.

Organic Flaxseed - and lots of it - was part of my regular diet.

Smoothies. Yogurt. Oatmeal. Sometimes 3–4 tablespoons a day - consistently, confidently - because I believed I was supporting my brain with omega-3s.

And for someone with APOE4/4, that felt like a smart move.

But it turns out, I was unknowingly working against myself.

The Unknown Factor: Sterol Hyperabsorption

What I didn’t know then - and what most people are never told - is that not everyone processes plant sterols the same way.

Some of us are sterol hyperabsorbers.

That means instead of efficiently eliminating plant sterols, we absorb them - and they accumulate in circulation - especially with APOE4s impaired cholesterol efflux.

The primary markers are:

• Beta-sitosterol

• Campesterol

At the extreme end of impaired sterol handling are rare genetic disorders like Niemann-Pick disease and sitosterolemia, where the body cannot process or eliminate certain lipids and sterols, leading to significant accumulation. So serious that - without treatment - premature death is the outcome.

That’s not what I’m suggesting here.

But it does illustrate an important point: sterol handling exists on a spectrum - and some of us sit further along that spectrum than we realize.

Most of us are never told this. We’re simply given generalized dietary advice and left to assume it applies equally.

Why This Matters (Especially for APOE4)

If you carry APOE4, lipid transport and metabolism are already different.

We are often told:

• Increase fiber

• Eat more plants

• Add seeds and nuts

• Focus on omega-3s

All good advice - in the right context.

But for a sterol hyperabsorber, loading up on foods like flaxseed, chia, nuts, and certain plant oils will increase sterol burden, not improve health.

So, you can be doing all the “right” things… and quietly moving in the wrong direction.

How I Found Out

I didn’t figure this out from a standard lipid panel. Everything looked… great!

It wasn’t until - in 2020 - I ran an advanced panel through Boston Heart Diagnostics that the picture became clear. My plant sterol markers were high.

As you can see above, not slightly - meaningfully. My cholesterol markers on this same test were Total Cholesterol 209, LDL-C 123, ApoB 103. Based on my goals today, everything was high - yet - for many folks not far off.

The Flaxseed Problem (for Some of Us)

Flax is often praised for:

• Fiber

• Lignans

• Omega-3 (ALA)

But it is also one of the highest dietary sources of plant sterols.

For a hyperabsorber, that matters.

In my case, what I thought was:
“I’m supporting my brain”

…was likely contributing to a risk exposure I was oblivious to.

Why You Should Know Your Pattern

This isn’t about demonizing healthy foods.

It’s about matching the input to your biology.

Two people can eat the same “clean” diet and have very different outcomes.

If you:

• Have persistently elevated LDL or ApoB despite a clean lifestyle

• Don’t respond well to statins alone

• See a strong response when adding ezetimibe

• Eat a diet high in nuts, seeds, and plant fibers

…it may be worth asking whether absorption - not production - is driving your numbers.

You Don’t Have to Guess

Ideally, this is tested.

The most direct way I’ve found is by measuring:

• Campesterol

• Beta-sitosterol

• Lathosterol

These markers help distinguish between cholesterol absorption and cholesterol production.

I used Boston Heart Diagnostics for this since most labs can’t test it. Even Emory University Hospital in Atlanta does not have a test to determine absorber status! But regardless of how you test, understanding your pattern can be a turning point.

The Takeaway

Health is not about doing more.

It’s about doing what matches you. For years, I was eating something, touted as a fantastic health food - and I was likely doing damage in the process.

Not everything that is “healthy” is healthy for everyone.

And sometimes, the most important step forward… is correcting what you’ve been doing all along.

If you carry APOE4 - or are working to optimize your cardiovascular and brain health - this is one area worth understanding.

Because the difference between absorption and production isn’t subtle.

It changes everything.

Two little-known compounds - palmitoylethanolamide (PEA) and luteolin - are attracting growing interest because they target a key driver of this process: the inflammatory feedback loop between mast cells and microglia.

Understanding this loop may open an entirely different way of thinking about brain protection.

The Brain’s Overlooked Immune Cells

When most people think about Alzheimer’s disease, they think about amyloid plaques and tau tangles.

But increasingly, researchers are focusing on the immune system of the brain.

Two types of cells appear particularly important:

Microglia
These are the brain’s resident immune cells. They patrol the nervous system, clear debris, and remove damaged synapses.

Mast cells
These cells sit near blood vessels and regulate inflammatory signaling.

Under normal circumstances, both of these cells are protective.

But when immune signaling becomes chronically activated, they can begin to amplify each other’s inflammatory responses.

This is where the mast cell - microglia loop comes into play.

The Mast Cell - Microglia Inflammatory Loop

Mast cells release powerful inflammatory molecules, including:

• histamine
• tryptase
• cytokines

These signals can activate nearby microglia.

Once activated, microglia release their own inflammatory mediators, including:

• IL-1β
• TNF-α
• reactive oxygen species

These molecules can further stimulate mast cells, creating a self-reinforcing inflammatory loop.

Over time, this process can create a chronic inflammatory environment that damages synapses and neurons.

For APOE4 carriers, whose immune signaling pathways appear to be more sensitive, this feedback loop may be particularly important.

Enter PEA

Palmitoylethanolamide (PEA) is a naturally occurring fatty-acid signaling molecule produced in the body.

It belongs to the same family as the endocannabinoids, although it does not bind directly to the classic cannabinoid receptors.

Instead, PEA activates a receptor called PPAR-alpha, which regulates inflammation and lipid metabolism.

When PEA levels rise, several important things happen:

• mast cells become more stable
• inflammatory cytokines decline
• microglial activation decreases
• oxidative stress is reduced

In other words, PEA helps restore immune balance rather than suppress immunity.

The goal is not to shut down the brain’s defenses, but to prevent them from becoming chronically overactive.

Luteolin: A Brain-Penetrating Flavonoid

Luteolin is a naturally occurring flavonoid found in foods such as:

• celery
• parsley
• artichokes
• chamomile

Unlike many plant compounds that struggle to reach the brain, luteolin crosses the blood–brain barrier.

Once in the brain, luteolin can:

• inhibit mast cell activation
• reduce histamine release
• suppress inflammatory cytokines
• calm microglial overactivation
• protect neurons from oxidative stress

These effects make luteolin a natural complement to PEA.

Why the Combination Matters

Individually, both compounds reduce inflammation.

Together, they appear to be synergistic.

PEA stabilizes mast cells and activates anti-inflammatory PPAR-alpha signaling.
Luteolin blocks inflammatory cascades such as NF-κB and cytokine release.

The result is a broader calming effect on the brain’s immune system.

Rather than suppressing immunity, the combination appears to shift immune cells back toward a more balanced, protective state.

A Surprising Link to Cholesterol Biology

One of the most intriguing aspects of PEA receives relatively little attention.

By activating PPAR-alpha, PEA may increase activity of cholesterol transport proteins such as:

• ABCA1
• ABCG1

These proteins move cholesterol out of immune cells and back into HDL particles - a process known as cholesterol efflux.

Why does this matter?

Because both atherosclerosis and Alzheimer’s disease involve immune cells overloaded with lipids.

In arteries, macrophages filled with cholesterol become foam cells, forming plaque.

In the brain, microglia can accumulate lipid droplets and become dysfunctional.

Supporting cholesterol efflux pathways may help restore healthier immune cell function in both systems.

For APOE4 carriers - who often have impaired lipid transport - this connection may be particularly important.

Clinical Use and Safety

In research and clinical settings, PEA is typically used in micronized or ultramicronized form, which improves absorption.

Typical dosing ranges:

PEA:
600–1200 mg per day

Luteolin:
50–100 mg per day

Some formulations combine both compounds in the same capsule.

Both compounds have an excellent safety profile, and side effects appear to be rare.

A Different Approach to Brain Protection

Most Alzheimer’s prevention strategies focus on metabolic health, lipid management, sleep, and exercise.

Those foundations remain essential.

But another layer is becoming increasingly clear: the regulation of brain immune signaling.

If microglia remain chronically activated for decades, they can gradually damage synapses and accelerate neurodegeneration.

Compounds such as PEA and luteolin offer a different approach - not by targeting amyloid directly, but by modulating the inflammatory environment in which neurodegeneration unfolds.

For APOE4 carriers, whose immune systems appear particularly sensitive, this strategy may prove especially relevant.

Alzheimer’s prevention may ultimately depend not only on clearing plaques, but on keeping the brain’s immune system balanced, calm, and capable of repair.

More on PEA:

https://pmc.ncbi.nlm.nih.gov/articles/PMC8157570/
https://pmc.ncbi.nlm.nih.gov/articles/PMC9496237/
https://pmc.ncbi.nlm.nih.gov/articles/PMC9405819/

You cannot manage what you don’t measure.

Most annual physicals include only a very limited set of lab tests. They are designed primarily to detect existing disease, not to help you understand how your biology is evolving over time.

If our goal is prevention - whether that’s cardiovascular disease, metabolic dysfunction, or Alzheimer’s disease - we need a much broader picture.

Why Standard Lab Panels Fall Short

A typical annual panel might include:

• total cholesterol

• fasting glucose

• a basic metabolic panel

That may be enough for basic screening, but it leaves out many of the markers that reveal early biological shifts years before disease appears.

For those of us trying to stay ahead of chronic disease, the real value lies in seeing what is changing before it becomes a diagnosis.

Accessing Comprehensive Testing

One service that makes broader testing accessible is Function Health. I was thrilled when that site was launched!

What makes their approach appealing is its simplicity:

• a large panel of biomarkers

• a single bundled price

• blood drawn locally at local labs

• results delivered through an online dashboard

For anyone interested in understanding their health more deeply, this kind of comprehensive panel can reveal a great deal more than a routine annual exam.

But obtaining the numbers is only the beginning.

The Problem With “Normal”

Most lab platforms (including Function Health) will simply tell you whether a value is within the reference range.

Those ranges are designed to detect disease.

They are not designed to identify emerging patterns.

And this is where many folks miss the real story.

Individual markers rarely provide the full picture. What matters far more is how markers relate to each other.

Pattern Recognition: Where the Insight Lives

Consider a common metabolic pattern.

Someone might have:

• fasting glucose in the normal range

• fasting insulin slightly elevated

• triglycerides gradually increasing

• HDL slowly drifting downward

None of these numbers may trigger a red flag on their own. But taken together, they form a recognizable pattern: early insulin resistance.

If this pattern is identified early, lifestyle changes can often reverse the trajectory long before diabetes ever develops.

or

Someone with:

• LDL cholesterol that appears acceptable

• triglycerides that are low

• HDL that looks healthy

At first glance, this panel appears reassuring.

But if ApoB is elevated, it tells a very different story. ApoB reflects the number of atherogenic particles circulating in the bloodstream, and that particle burden is one of the strongest drivers of plaque formation.

Without looking at ApoB - and without recognizing how it relates to the rest of the lipid panel - this risk can easily remain hidden.

Another pattern shows up often in people struggling with fatigue or cognitive fog.

You might see:

• a TSH that appears normal

• free T3 sitting at the lower end of the range

• reverse T3 somewhat elevated

• ferritin trending low

Each marker alone might be labeled “normal.” But together they can suggest reduced thyroid hormone utilization, something that can affect energy metabolism and brain function.

Again, the insight comes not from a single number but from the relationship between them.

Turning Data Into Understanding

With the vast amount of data obtained from my labs, I use LabClarity as my educational resource which provides context around biomarkers and helps highlight patterns that may otherwise be easy to miss. What I appreciate about it is that it brings this information into one place, providing context around biomarkers and helping highlight patterns that might otherwise be easy to miss.

It’s been an invaluable way for me to learn what my numbers may be telling me when viewed together.

The Real Value of Testing

For those of us focused on preventing cardiovascular disease, metabolic dysfunction, and neurodegenerative conditions, understanding the relationships between various markers can make all the difference.

And there’s another reality we live in: Physicians simply don’t have the time to sit down with patients and walk through dozens of biomarkers in detail. Which means that if we want to understand what’s happening in our own bodies, we have to take an active role. We have to become our own health advocates. And that starts with educating ourselves - learning what the markers mean, how they interact, and what signals they may be sending long before disease ever appears.

While none of my neighbors can see me, if they could they might reasonably conclude I’ve lost my mind. Each morning I turn on 1970s disco music, step onto a rebounder on my deck, and start bouncing.

It probably looks ridiculous.

But over time I’ve come to believe this simple habit may be one of the most underrated forms of movement for long-term health. Rebounding also lets me stack another habit at the same time. While I’m bouncing on the deck, I’m soaking up the morning and/or evening sunlight and getting a healthy dose of the sun’s red and near-infrared rays.

Here’s why I do it:

1. Rebounding stimulates the lymphatic system

Unlike the cardiovascular system, the lymphatic system has no pump.

Lymph fluid relies largely on muscle contraction and body movement to circulate. This fluid carries immune cells, metabolic waste products, and inflammatory debris away from tissues.

Gentle vertical acceleration - like the up-and-down motion of rebounding - appears particularly effective at stimulating lymph flow.

Early NASA work examining different exercise modalities noted that rhythmic bouncing movements produced strong lymphatic circulation with relatively low joint stress.

In practical terms, that means rebounding helps support:

• immune function
• detoxification pathways
• tissue fluid balance

While formal lymph-flow studies are limited, the biomechanics make intuitive sense. The shifting G-forces created by bouncing likely generate a gentle compression that helps move cellular waste out of tissues.

2. It is an unusually efficient cardiovascular exercise

Rebounding creates repeated cycles of acceleration and deceleration.

With each bounce, the body experiences small shifts in gravitational force. These shifts require constant engagement of stabilizing muscles and cardiovascular adjustments.

Studies comparing rebounding to treadmill running have found that rebounding can produce similar oxygen consumption with significantly lower impact forces.

That makes it appealing for:

• older adults
• people with joint issues
• those seeking low-impact aerobic exercise

In other words, you can achieve meaningful cardiovascular stimulation without pounding your joints.

3. It activates muscle and bone without high impact

Every bounce involves rapid cycles of:

• muscle contraction
• eccentric loading
• stabilization

These small forces repeatedly stimulate:

• postural muscles
• lower-body muscle fibers
• bone mechanoreceptors

Mechanical loading - even at modest levels - is one of the key signals that helps maintain bone density and muscle function with age.

Because rebounding distributes force across the trampoline surface, the impact is much lower than running or jumping on hard ground.

4. It may support metabolic health

Like other rhythmic aerobic activity, rebounding improves:

• circulation
• insulin sensitivity
• mitochondrial activity

But it also has an additional advantage: it is easy to do frequently.

Many people struggle to fit longer workouts into daily life. Rebounding allows you to accumulate meaningful metabolic movement in short bursts throughout the day.

Even five to ten minutes of rhythmic movement can improve glucose handling after meals.

5. It appears to improve balance and coordination

The unstable surface of a rebounder requires constant micro-adjustments of posture and balance.

These adjustments engage:

• core muscles
• stabilizing muscles of the hips and ankles
• proprioceptive feedback systems

Maintaining these systems becomes increasingly important as we age.

Balance training is strongly associated with fall prevention and long-term mobility.

6. Possible brain benefits

Direct research on rebounding and brain health is limited, but several mechanisms suggest potential benefits.

Rhythmic aerobic movement increases:

• cerebral blood flow
• neurotrophic signaling (such as BDNF)
• metabolic flexibility

Exercise also improves glymphatic clearance, the system the brain uses to remove metabolic waste during sleep - great for APOE4 carriers!

Rebounding may add an additional element: mild gravitational variation, which some researchers believe can influence fluid dynamics in the brain and spinal system.

This area remains largely speculative, but it is biologically plausible.

Why I do it

For me, rebounding checks several boxes at once.

It is:

• low-impact
• metabolically stimulating
• easy to do daily - and more than once
• surprisingly energizing

and FUN!

Ten minutes of bouncing is often enough to increase heart rate, improve circulation, and start the day with movement. I often add 3-5 lb weights.

Most importantly, it is something I can maintain consistently.

And consistency matters far more than perfection. In case you wonder, the rebounder I use is a 44” diameter Bellicon.

Addendum: The Astronaut / Neurology Insight

Researchers studying astronauts found that rhythmic vertical acceleration changes how cerebrospinal fluid moves through the brain and spinal canal.

In microgravity, CSF circulation becomes abnormal, which is one reason astronauts sometimes develop vision changes and intracranial pressure problems.

On Earth, rebounding produces repeated mild acceleration and deceleration forces that affect the same fluid dynamics.

The effect:

• alternating pressure gradients in the spine
• improved CSF pulsation
• improved venous drainage from the brain

These factors influence glymphatic flow.

Why This Matters for Brain Detox

The glymphatic system clears:

• beta-amyloid

• tau proteins

• metabolic waste

It works best when:

• CSF circulation is strong
• venous drainage is unobstructed
• lymphatic vessels in the neck are active.

Rhythmic body movement helps all three.

Why Rebounding Is Particularly Effective

Rebounding creates a unique combination:

Acceleration + decompression cycles

When you bounce:

1. Downward force
   → pushes lymph and venous blood upward

2. Upward release
   → reduces pressure and allows refill

This acts like a pump for lymph and venous return, which indirectly improves CSF exchange.

NASA researchers noted that rebounding can stimulate circulation more efficiently than running with lower oxygen demand.

A Simple “Brain Clearance Bounce”

You can add this small sequence after your rebound session.

2–3 minutes

1️⃣ Gentle bounce
2️⃣ Slow nasal breathing
3️⃣ Relax shoulders and neck

Then add:

30 seconds

Look slightly upward and gently extend the neck.

This position opens the jugular venous drainage pathways, which are critical for brain waste removal.

Why Neck Position Matters

The brain clears waste through:

• jugular veins
• meningeal lymphatic vessels

These run through the neck.

Poor posture or tight neck muscles can reduce drainage.

The gentle rebound + upright posture encourages venous outflow from the brain.

Before going further, it helps to clarify the terminology, because confusion around NAD is common.

NAD (nicotinamide adenine dinucleotide) is a molecule present in every cell. It exists in two forms: NAD (oxidized) and NADH (reduced). Together, they regulate redox balance, mitochondrial energy production, DNA repair, and cellular stress signaling.

NAD itself is not easily absorbed as an oral supplement in a way that meaningfully raises intracellular levels. Instead, most interventions aim to increase NAD through precursors:

• NMN (nicotinamide mononucleotide) – a direct precursor to NAD⁺

• NR (nicotinamide riboside) – another precursor that converts into NMN and then into NAD⁺

Both NMN and NR are used with the goal of raising intracellular NAD levels. They are not interchangeable with NAD itself, they are upstream building blocks.

When we discuss “boosting NAD,” we are generally referring to increasing cellular NAD availability via these precursor pathways.

NAD is not a “supplement topic.” It is a systems topic.

Nicotinamide adenine dinucleotide (NAD⁺/NADH) sits at the center of cellular energy metabolism. But the reason I’m writing about it in the context of APOE4 is more specific:

If APOE4 increasingly looks like a lipid trafficking vulnerability, then NAD is one of the most plausible upstream determinants of how well the system tolerates lipid load.

Lipid transport and recycling are not passive processes. They require energy, intact redox balance, functional mitochondria, and adequate cellular housekeeping. NAD touches all of those domains.

The core connection: lipid trafficking is energy-expensive

APOE4 vulnerability is often described as “lipid handling gone wrong.” But the practical question is: what makes lipid handling fail?

In the real world, lipid trafficking becomes pathological when cells cannot:

• oxidize and utilize lipids efficiently

• remodel and repair membranes

• clear damaged lipid and protein complexes

• maintain a stable inflammatory set point

All of those functions become strained when NAD availability falls.

What recent research is emphasizing

Across animal, mechanistic, and translational work, three themes are showing up repeatedly:

1) NAD depletion appears to be part of the Alzheimer’s biology, not just aging background noise

Multiple lines of research point to disturbed NAD metabolism in Alzheimer’s models and human AD biology, including increased NAD consumption in inflammatory glial environments (e.g., CD38 induction in astrocytes/microglia around pathology).

2) Boosting NAD can improve mitochondrial stress responses and cellular resilience in AD models

A 2024 paper reported that NMN (an NAD⁺ precursor) improved mitochondrial stress response pathways in an Alzheimer’s context via ATF4-dependent mitochondrial UPR signaling.

Other recent mechanistic work highlights new regulators of brain NAD levels (including astrocyte-linked pathways involving CD38), with tauopathy protection in mouse models when brain NAD is augmented.

3) Human data are emerging.

A randomized placebo-controlled trial of nicotinamide riboside (NR) in older adults with MCI showed that NR increased blood NAD levels and was well tolerated, but did not produce a clear cognitive improvement over the short study duration.

That pattern matters: NAD may be upstream and permissive. It may shift biology and resilience before it shifts test scores - especially over short windows.

Why NAD matters specifically for APOE4 lipid trafficking

Here is the simplest way to frame it:

APOE4 struggles most when lipid handling occurs in a hostile environment.
NAD is one of the strongest determinants of whether the environment is hostile or permissive.

1) NAD supports mitochondrial lipid utilization

When NAD is low, mitochondrial throughput declines. Fatty acid oxidation and energy production become constrained, and lipids are more likely to be diverted into storage (lipid droplets) rather than processed. In glial cells, this shift is tightly linked to inflammatory reprogramming.

2) NAD supports membrane maintenance and repair

Membranes are not static. They are constantly remodeled, repaired, and replaced. That’s the premise of Lipid Replacement Therapy. NAD-dependent enzymes and NAD-linked metabolic capacity influence whether membrane repair is robust or brittle, especially under oxidative stress.

3) NAD influences whether glia resolve lipid stress or amplify it

In the Alzheimer’s literature, NAD-consuming CD38 is repeatedly implicated in inflammatory glial environments. CD38 dysregulation in the brain is increasingly studied as an immunometabolic checkpoint, and recent work has explored CD38-targeted strategies that restore metabolic fitness and reduce neuroinflammation in AD models.

For APOE4, this matters because microglia and astrocytes are the front line of lipid recycling. If they become energetically compromised, lipid trafficking becomes inflammatory trafficking.

“Very recent” developments worth watching

A cluster of 2025 publications has accelerated interest in NAD as a disease-modifying axis, including mechanistic work describing NAD regulation through astrocyte pathways and tauopathy protection.

There is also emerging preclinical work exploring pharmacologic preservation of NAD balance with striking claims in animal models (including the suggestion that delayed intervention can still shift pathology). These are early-stage results and should be interpreted as hypothesis-strengthening rather than practice-changing.

At the review level, the broader scientific consensus trend is also visible: NAD augmentation is increasingly framed as a multi-target strategy relevant to neurodegeneration through energy metabolism, proteostasis, and neuroinflammation.

How I integrate NAD into the lipid trafficking framework.

I view NAD as the energetic layer that helps determine whether:

• lipid trafficking remains efficient or congested

• membranes remain resilient or oxidizable

• glia remain homeostatic or reactive

• autophagy keeps pace with damage or falls behind

In other words, NAD doesn’t replace the lipid story. It supports the conditions under which the lipid story stays quiet.

Where this leaves us.

The NAD story is compelling because it is coherent across multiple levels of biology. But it is also important to be intellectually honest:

• Human RCTs to date are small and short

• Cognitive endpoints may lag behind mechanistic changes

• Optimal dosing, duration, and target populations are not settled

Still, for APOE4 prevention-minded individuals, NAD is difficult to ignore precisely because it maps onto the vulnerabilities we are now zeroing in on: lipid trafficking stress, mitochondrial fragility, glial reactivity, and impaired repair capacity.

References:
https://pmc.ncbi.nlm.nih.gov/articles/PMC7963035/
https://pmc.ncbi.nlm.nih.gov/articles/PMC11470026/
https://pmc.ncbi.nlm.nih.gov/articles/PMC12866132/
https://pmc.ncbi.nlm.nih.gov/articles/PMC7238909/

Disclaimer: This post is for educational discussion only and does not constitute medical advice. NAD-related interventions (including precursors such as NMN/NR or NAD infusions/injections) can have risks and may not be appropriate for everyone. Decisions should be made with a qualified clinician, particularly for individuals with complex medical histories or those using off-label therapies

A recently published paper adds to that picture by examining how the gut microbiome differs between APOE4 carriers and non-carriers in cognitively healthy older adults. The differences are subtle, but they matter because they point to low-risk, high-upside ways APOE4 carriers can reduce inflammatory pressure and support the systems that APOE4 strains over decades.

What the study looked at

Researchers analyzed stool samples from 114 cognitively healthy adults (average age ~77) and compared APOE4 carriers with non-carriers. Importantly, these were not people with Alzheimer’s. These were older adults aging normally.

That matters, because it shifts the question from disease to risk biology.

The key finding

APOE4 carriers did not have worse overall microbiome “richness” (how many species live in the gut). But they did show differences in microbial composition compared to non-carriers.

In other words:

• It’s not about how many microbes you have

• It’s about which ones dominate and what they do

Notably, the study highlighted species differences tied to short-chain fatty acid (SCFA) pathways, including butyrate—a compound associated with:

• Gut barrier integrity

• Immune regulation

• Microglial balance

• Neuroinflammation control

This aligns with the broader pattern across APOE–microbiome research: the most consistent signal isn’t one “magic bacteria,” it’s function - inflammation tone, barrier integrity, and microbial metabolites like SCFAs.

Where lipid transport fits in

APOE4’s core problem in the brain isn’t “cholesterol is bad.” It’s that lipids and cholesterol aren’t moved around as efficiently, especially for repair and maintenance.

Think of ApoE as a delivery system: neurons and synapses rely on lipid transport for membrane repair, signaling, and resilience. APOE4 tends to be a less efficient delivery version, and it’s more vulnerable when inflammation is high.

This is where the gut matters.

The gut can worsen or ease APOE4’s lipid-transport burden in 3 practical ways:

1) Inflammation is a headwind for lipid handling
A disturbed microbiome can increase inflammatory signaling through the immune system. Chronic, low-grade inflammation makes the brain’s support cells (astrocytes and microglia) less “repair oriented,” which is the exact environment where APOE4 struggles most.

2) The gut helps regulate bile signaling and fat processing
Our gut microbes interact with bile acids (which start as cholesterol). Those bile-related signals influence metabolic tone and inflammatory set points. When that system is off, lipid handling tends to get messier, systemically and in the brain.

3) SCFAs help keep the barrier intact
Butyrate-supportive ecosystems are linked with healthier gut barrier function and calmer immune signaling. A better barrier typically means fewer inflammatory triggers leaking into circulation - again lowering the pressure on APOE4’s already-fragile risk biology.

Bottom line: Supporting gut function can lower the inflammatory “noise” that makes APOE4 lipid transport inefficiency more damaging over time.

What we can reasonably extrapolate (and what we can’t)

Taken in context with other studies in humans and APOE-targeted replacement mice, this paper supports a larger pattern:

• APOE4 is associated with a pro-inflammatory bias

• The gut microbiome appears to be one contributor to that bias

• SCFA-supportive ecosystems may be less supported in APOE4 carriers

• That may amplify vulnerability over decades

Crucially, the microbiome is modifiable - unlike our genes.

Where TUDCA fits into the APOE4 gut-lipid picture
An often-overlooked piece of gut health is bile flow and bile signaling, which sits at the intersection of cholesterol metabolism, microbial ecology, and inflammation. TUDCA (tauroursodeoxycholic acid) supports healthy bile composition and flow, helping the body properly emulsify fats and recycle cholesterol-derived bile acids. This matters for APOE4 because bile acids are not just digestive detergents - they are signaling molecules that influence metabolic tone, inflammatory pathways, and gut microbial balance. When bile flow is sluggish or bile signaling is disrupted, downstream effects can include dysbiosis, impaired lipid handling, and increased inflammatory burden - all areas where APOE4 carriers are more vulnerable. By supporting bile physiology, TUDCA may indirectly reduce stress on lipid transport systems and help create a gut environment that is more compatible with long-term metabolic and brain resilience.

An APOE4-focused action plan (low risk, high upside)

Rather than chasing individual bacteria, the goal is to shift gut function, not taxonomy.

Start with data

If you’ve never done a microbiome stool test, this is an excellent place to start. Many of us have taken antibiotics at some point, and those are well known to disrupt beneficial gut bacteria. A microbiome test removes the guesswork and allows you to build a targeted, informed action plan.

Looking back at my own results, I learned I was low in key strains such as Akkermansia and L. reuteri, which helped me adapt my strategy with precision. Tiny Health, a leader in microbiome testing, offers a simple at-home test with clear, actionable insights. Use code APOE44 to save $20 on your test.

1) Support short-chain fatty acid production

SCFAs, especially butyrate, are one of the most consistent protective signals in gut–brain research.

Practical ways to do this:

• Gradually increase fermentable fiber diversity, not just quantity

• Examples: overnight oats or barley (beta-glucans), legumes if tolerated, psyllium, PHGG, inulin, cooked-and-cooled starches

• Go slow—tolerance matters more than perfection

2) Use fermented foods strategically

Small, regular amounts can help reshape microbial signaling:

• Kefir, yogurt, sauerkraut, kimchi, fermented vegetables

• Start with tablespoons, not bowls

• Back off if histamine or GI symptoms flare

3) Think “polyphenols feed microbes”

Polyphenols can shift microbial function even when species changes are subtle:

• Berries, cocoa, green tea, herbs, spices, pomegranate

4) Protect the gut barrier

A stressed gut barrier can amplify systemic and neuroinflammation.

• Minimize ultra-processed foods (and pay attention to emulsifiers if sensitive)

• Be mindful with alcohol

• Prioritize sleep and circadian consistency

• Ensure adequate omega-3 intake

5) Be intentional after antibiotics or illness

Treat recovery periods as “rebuild windows”:

• Re-emphasize fibers, fermented foods, and polyphenols

• Don’t assume you “bounce back” automatically

What I personally do to support gut health

After years reading about the gut–brain connection (and taking a microbiome test), I’ve landed on an approach that’s simple, consistent, and physiologically sensible rather than extreme.

My non-negotiable foundation is real food - focused on supporting the gut lining and microbial diversity:

• Homemade kefir (which I tolerate well and make regularly)

• Non-pasteurized sauerkraut for natural lactobacilli and fermentation byproducts

• A diet that excludes ultra-processed foods, sugar, simple carbs, and seed oils

On top of that base, I use a few targeted supports:

• Butyrate (mornings, empty stomach) to support gut barrier integrity

• TUDCA (with breakfast) to support bile flow and fat digestion—an often-overlooked part of gut health

• Akkermansia (Pendulum) and L. reuteri as targeted supports rather than “dozens of strains” … both also taken on an empty stomach.

Where saffron fits in (and why I’ll continue using it)

One addition that’s been surprisingly impactful for me is saffron. (wrote about its potent effects in a previous post.)

From a metabolic perspective, saffron supports:

• insulin sensitivity

• reduced inflammatory signaling that interferes with glucose regulation

• healthier gut–liver–bile signaling (which affects metabolic control)

The bigger picture

For APOE4 carriers, gut health isn’t just digestive health. It’s brain health.

Genes load the gun, but environment pulls the trigger - and the microbiome is one of the most powerful, most modifiable environmental levers we have.

And unlike many interventions in Alzheimer’s prevention, improving gut ecology is:

• low risk

• multi-system beneficial

• compatible with almost every other strategy

This isn’t about doing everything.
It’s about doing enough of the right things, consistently - and paying attention to how our body responds.

References:
https://pmc.ncbi.nlm.nih.gov/articles/PMC12737834/
https://pmc.ncbi.nlm.nih.gov/articles/PMC6593891/
https://pmc.ncbi.nlm.nih.gov/articles/PMC12081816/
https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2021.619051/
https://www.sciencedirect.com/science/article/pii/S2589004224015736

Triglycerides are often discussed as if they’re metabolic waste, something to suppress aggressively. But biologically, triglycerides are part of the system that keeps lipids contained, buffered, and well-behaved. Treating them as disposable misses what they actually do - both in circulation and inside cells, including in the brain.

If this sounds familiar, it should. I made a similar point in an earlier post on statins: lipid biology rarely rewards absolutism. “Lower” can be helpful - until it isn’t. Triglycerides may be the clearest example of where that line gets crossed.

And for anyone thinking about Alzheimer’s risk, APOE genotype, or aging physiology, this nuance matters.

Triglycerides aren’t just a blood number

Yes, fasting triglycerides largely reflect triglyceride-rich lipoproteins (mostly VLDL). And yes - chronically elevated triglycerides in midlife often signal insulin resistance, excess remnant particles, fatty liver, and higher cardiovascular risk.

That part of the story is real.

But triglycerides are also the backbone of lipid droplets - dynamic intracellular organelles found in liver, muscle, immune cells, and importantly, astrocytes in the brain. Lipid droplets are not passive fat storage. They are a containment system.

They exist to:

• safely sequester fatty acids

• prevent lipotoxicity

• buffer oxidative stress

• supply energy during demand

• protect mitochondria from overload

In other words, triglycerides are one of the ways biology keeps lipids from misbehaving.

Lipid droplets need triglycerides to stay functional

Here’s where things get interesting - and where the “lower is better” narrative starts to wobble.

Recent cellular work shows that the ratio of triglycerides to cholesteryl esters inside lipid droplets affects their physical state. When triglycerides are depleted—such as during sustained lipolysis or severe energy restriction - lipid droplets can undergo phase transitions, shifting toward more rigid, liquid-crystalline states.

Why does that matter?

Because fluid lipid droplets behave differently than rigid ones. Organization matters. Mobility matters. And rigidity tends to show up under metabolic stress.

Triglycerides, in sufficient proportion, help keep lipid droplets fluid and functional. This is not about excess. It’s about balance.

That idea aligns surprisingly well with broader work on phase separation and membrane dynamics, a conceptual framework explored by researchers like Doris Loh and discussed in a previous post. The takeaway isn’t that triglycerides are “protective” in isolation - but that biology cares about structure and organization, not just concentrations.

APOE, triglycerides, and why genotype matters

This is where the Alzheimer’s conversation becomes unavoidable.

Astrocytes - the brain’s lipid managers- use APOE to traffic lipids. Under lipogenic conditions, APOE itself associates with lipid droplets. When APOE is dysfunctional, lipid droplet handling changes.

Astrocytes expressing APOE4, in particular, form lipid droplets that are more vulnerable to oxidative damage and impaired turnover. That suggests lipid containment and buffering may already be compromised in APOE4 brains.

So what happens if we push triglycerides aggressively lower - without regard to cellular lipid handling?

We don’t fully know. But we should at least pause.

The APOE2 paradox (and why it should make us think)

Here’s a fact that surprises many people:

APOE2 is the most protective genotype for Alzheimer’s disease risk.

And yet - APOE2 homozygotes (2/2) are also the group most prone to elevated triglycerides and delayed remnant clearance.

I stumbled onto this while analyzing my APOE2/2 husband’s lipid profile. His triglycerides consistently run higher, increasing his cardiovascular risk, yet his genetics are strongly protective against Alzheimer’s disease.

That does not mean high triglycerides are beneficial. It means the relationship between triglycerides, lipid trafficking, and brain health is not linear.

If the genotype most protective against Alzheimer’s tends to tolerate - or even trend toward - higher triglycerides, then blanket claims that triglycerides should be driven as low as possible for everyone deserve closer scrutiny.

Context matters. Genetics matters. Mechanism matters.

And yes - as a 4/4 myself, I did manage one major strategic win: choosing a 2/2 husband to offset our children’s AD risk. A rare gem indeed - only about 0.5–1% of the population.
Genetics is humbling… but not entirely without humor and irony.

When low triglycerides may actually be a signal

Several large observational studies in older adults have shown something deeply unfashionable:

• Very low triglycerides are associated with higher dementia risk

• In the “oldest old,” higher triglycerides correlate with lower risk of cognitive decline, frailty, and mortality

• Low triglycerides have been associated with increased hemorrhagic stroke risk

This does not mean anyone should aim to raise triglycerides. It means that in late life - or in people who are under-fueling, over-restricting, or stacking triglyceride-lowering interventions - very low triglycerides may reflect loss of metabolic reserve, not metabolic excellence.

Medicine is good at lowering numbers. It’s less good at asking what those numbers represent in context.

APOE4, DHA delivery, and lipid transport

Work by researchers like Dr. Hussein Yassine has highlighted another important point: lipid delivery to the brain differs by APOE genotype.

In DHA supplementation studies, APOE4 carriers show reduced enrichment of CSF omega-3s compared with non-carriers - suggesting transport, not intake, may be the bottleneck.

This reinforces the broader theme:
In APOE4, lipid handling matters as much as lipid levels.

Driving triglycerides ever lower without considering how lipids are trafficked, stored, and delivered - especially in the brain - may solve one problem while quietly creating another.

So what’s the sane position?

Here’s my thought:

• In midlife, elevated triglycerides often reflect metabolic dysfunction and should be addressed - primarily by fixing insulin resistance, not just suppressing the number.

• In later life, very low triglycerides can be a warning sign of under-fueling, frailty, or diminished resilience.

• For APOE4, lipid organization and delivery may matter more than achieving textbook-perfect fasting values.

Biology rarely rewards extremes.

When might triglycerides be “too low”?

There is no universally agreed cutoff - but observational studies linking low TG to dementia, frailty, or hemorrhagic stroke often involve fasting triglycerides below ~60 mg/dL, and sometimes below 50 mg/dL, particularly in older adults.

Low triglycerides deserve a second look when they coexist with:

• unintentional weight loss or sarcopenia

• aggressive carbohydrate or fat restriction

• excessive fasting in older age

• fatigue, poor sleep, cold intolerance

• low insulin, low leptin, or other signs of under-fueling

This is not a call to raise triglycerides.
It is a call to stop celebrating low numbers without context.

Closing thought

Triglycerides are not merely a risk marker to be crushed into submission. They are part of the system that keeps lipids organized, contained, and less toxic - both in plasma and inside cells.

If APOE2 homozygotes can carry higher triglycerides yet enjoy the lowest Alzheimer’s risk, that alone should make us skeptical of one-size-fits-all lipid dogma.

What Did the Study Find?

Published in Nature after more than a decade of work, this study shows that:

• Lithium is naturally present in the brain. Until now, most research treated lithium mainly as a pharmaceutical used in psychiatric conditions like bipolar disorder. But this team demonstrated that lithium exists at biologically meaningful levels in healthy brains.

• Lithium levels drop early in Alzheimer’s. In both human brain tissue and animal models, lithium depletion was one of the first detectable changes associated with cognitive impairment.

• Plaques may sequester lithium. Amyloid-beta, the early hallmark protein aggregates in Alzheimer’s, binds lithium - reducing its availability in the brain.

• In mice, lithium deficiency accelerated pathology. Lower lithium levels triggered inflammation, synaptic loss, myelin degradation, and memory decline, all classic Alzheimer’s features.

• A lithium compound reversed disease markers in mice. Using a compound called lithium orotate that avoids being sequestered by amyloid, researchers were able to restore memory and reduce pathology in mice - at doses far lower than those used in bipolar treatment.

This last point is especially important because lithium in high doses (such as lithium carbonate used in psychiatric settings) can be toxic, especially in older adults. The notion here is micro- or physiological dosing of lithium, not high, mood-stabilizing levels.

Why Lithium Might Work: The GSK-3 Connection

One reason lithium keeps resurfacing in Alzheimer’s research - despite decades of neglect - is its relationship to a powerful regulatory enzyme called GSK-3 (glycogen synthase kinase-3).

What is GSK-3?

GSK-3 is a master regulatory kinase - an enzyme that controls the activity of many other proteins by phosphorylating them. In a healthy brain, GSK-3 activity is tightly restrained. In Alzheimer’s disease, it becomes chronically overactive.

That matters because GSK-3 sits at the crossroads of several core Alzheimer’s processes:

• Tau pathology:
  GSK-3 is one of the primary enzymes that hyperphosphorylates tau. Excessive GSK-3 activity destabilizes microtubules, promotes neurofibrillary tangles, and closely tracks cognitive decline.

• Amyloid biology:
  GSK-3 promotes amyloid-β production and is itself activated by amyloid, creating a self-reinforcing feedback loop that accelerates pathology once it begins.

• Neuroinflammation:
  Overactive GSK-3 drives pro-inflammatory signaling (via NF-κB and cytokines), keeping microglia in a chronically activated, neurotoxic state.

• Insulin resistance in the brain:
  Insulin signaling normally suppresses GSK-3. In Alzheimer’s - and particularly in APOE4 brains - impaired insulin signaling removes this brake, allowing GSK-3 to remain switched “on.”

• Mitochondrial dysfunction and synaptic loss:
  GSK-3 overactivity disrupts energy production, impairs synaptic plasticity, and promotes neuronal apoptosis.

In short, GSK-3 doesn’t cause one Alzheimer’s feature - it coordinates many of them.

Where lithium fits in

Lithium is one of the most potent known inhibitors of GSK-3.

At low, non-psychiatric doses, lithium:

• Directly inhibits GSK-3 activity

• Indirectly suppresses GSK-3 by improving insulin signaling

• Reduces tau hyperphosphorylation

• Dampens neuroinflammatory signaling

• Supports autophagy and mitochondrial function

This is a fundamentally different mechanism than targeting amyloid plaques or tau tangles after the fact. Lithium acts upstream, at a control node that influences both.

Importantly, this does not require the high serum lithium levels used in bipolar disorder, levels that carry real toxicity risks. The emerging Alzheimer’s literature increasingly points toward micro-dosing, where GSK-3 is gently down-regulated rather than shut down.

Why this connection is often missing from the literature

Most Alzheimer’s papers focus on isolated pathways such as tau, amyloid, inflammation, metabolism, rather than the enzymes that integrate them. GSK-3 often appears in the background of these studies, but rarely as the central unifying factor.

When viewed through a systems-biology lens, however, the logic becomes difficult to ignore:

If Alzheimer’s represents a state of chronic GSK-3 overactivation, then lithium’s long-observed neuroprotective effects suddenly make sense.

This doesn’t make lithium a cure, but it does make it a rational intervention worth serious attention.

Bottom line

Lithium’s relevance to Alzheimer’s is not mysterious or anecdotal. It stems from its ability to modulate GSK-3, a central enzyme linking tau pathology, amyloid biology, inflammation, insulin resistance, and neuronal survival. Seen this way, lithium is not an outlier, it is one of the few interventions that acts where many Alzheimer’s pathways converge.

Why Is This Important?

For decades, Alzheimer’s research has focused heavily on amyloid plaques and tau tangles, with limited success in changing clinical outcomes. This study proposes a fundamentally different angle:

Instead of focusing solely on downstream pathology, look upstream to an essential trace element whose deficiency may open the door to neurodegenerative cascades.

Some prior population studies had hinted that areas with higher natural lithium in drinking water had lower dementia rates, and long-term lithium therapy in psychiatric patients has been associated with lower Alzheimer’s incidence.

Mechanisms by Which Lithium Might Help

Lithium has been studied for its neuroprotective properties for years. Preclinical and clinical research has shown that it may:

• Inhibit GSK-3, an enzyme involved in both amyloid and tau pathology.

• Reduce neuroinflammation and oxidative stress.

• Improve cell survival, mitochondrial function, and autophagy - all processes implicated in Alzheimer’s.

• Correlate with slower cognitive decline in some human studies.

The new Harvard work extends these concepts by suggesting that the brain actually needs a baseline lithium level for normal function - much like essential vitamins or minerals - and that depletion is not just an association but a contributor to disease progression.

Important Caveats

This research is still in early stages:

• Most of the dramatic effects were observed in mouse models, which don’t always translate directly to humans.

• Clinical trials in humans for Alzheimer’s prevention or therapy using lithium have been limited and mixed, and no lithium compound is currently approved for Alzheimer’s treatment.

• The form of lithium used in the mice (e.g., lithium orotate or other amyloid-evading compounds) has not yet been tested in robust, controlled human trials.

Where this field might head next:

The implications of this research extend beyond a single study:

• Biomarker development: Measuring lithium levels in blood or cerebrospinal fluid might help identify individuals at risk for Alzheimer’s earlier.

• New therapeutic strategies: Designing lithium compounds that avoid sequestration and toxicity could lead to treatments that modify the disease process rather than just its symptoms.

• Nutritional neuroscience reconsidered: If lithium is truly acting like an essential nutrient for brain health, baseline requirements and dietary/lifestyle factors may gain newfound importance.

Bottom Line

Emerging research is reframing lithium from a psychiatric drug to a potential missing piece in our understanding of Alzheimer’s disease. While it’s too early to declare it a cure or a clinically validated therapy, the idea that lithium deficiency might help explain and potentially treat or prevent Alzheimer’s is a bold and testable hypothesis that has ignited scientific interest.

For this APOE4/4 carrier, and already beyond the average age of Alzheimer’s onset for many with my genotype - waiting passively for research to “catch up” is not an option. I’ve spent years studying the lithium literature and am comfortable with the risk–benefit profile at very low doses. Based on that work, I take 5–10 mg of lithium orotate nightly, a practice I began a few years ago after reading a 2015 study suggesting lithium’s potential to support cognition. For me, this is not experimentation, it’s an informed, measured decision grounded in science, context, and personal risk tolerance.

Other references:

https://pubmed.ncbi.nlm.nih.gov/19754466/

https://pubmed.ncbi.nlm.nih.gov/29232923/

https://pubmed.ncbi.nlm.nih.gov/?term=lithium+alzheimer%27s

https://www.science.org/content/article/could-lithium-stave-alzheimer-s-disease?

https://www.sciencedirect.com/science/article/abs/pii/S0304394021004225?via%3Dihub

Tolion Health AI is looking for APOE4/4 carriers willing to participate in a short live feedback session to help shape the development of a new app: Tolion Brain Coach.

Tolion was founded by Dr. Martin Tolar, the same physician-scientist behind Alzheon’s ALZ-801, a targeted therapy developed specifically for APOE4-related Alzheimer’s risk.

Tolion is currently gathering feedback on an early version of the app and looking to learn from real experiences within the APOE4/4 community.

Participants who complete a 1-hour video call will receive a $50 Amazon gift card as a thank-you.

If you’re APOE4/4 and interested in contributing to tools being built for our community, you can learn more and sign up here:

https://forms.gle/xz56Hm92x8v1UybdA

In 2023, my HbA1c hovered around 5.5%, just one decimal point shy of being labeled pre-diabetic. That number alone was enough to push me into action. I decided to wear a CGM (continuous glucose monitor) because I wanted to understand what was actually happening beneath the surface - and why, despite what I believed were healthy food choices, my A1C was this high.

What I saw was sobering.

My average glucose was around 110 mg/dL, and foods widely considered “healthy” - apples, bananas, even very modest portions of starch - sent my glucose soaring. Seeing those spikes in real time was a shock. I had no idea how frequently my glucose was being yanked upward, despite what I thought was a careful, whole-food diet.

The Cost of “Doing Everything Right”

By 2025, I managed to bring my average glucose down to about 89 mg/dL (CGM reading below) - but the price was steep.

I achieved those numbers only by becoming extremely restrictive:

• avoiding entire food groups

• eating very little variety

• constantly anticipating spikes

• and, ultimately, losing weight I couldn’t afford to lose

On paper, my metabolism looked much better.
But my 5’7” frame was beginning to look uncomfortably thin as my weight dipped below 120 lbs.

By late summer last year, I made a hard but necessary decision: I would stop trying to improve insulin sensitivity temporarily and focus solely on regaining weight. Being underweight was a more immediate health risk than a borderline A1C.

Letting Go of the CGM (and the Rules)

In August, I stopped using my CGM altogether. I stopped checking finger sticks. I stopped worrying about spikes.

I ate anything I wanted - as long as it was whole food. And yes, I broke some rules. Even Ice cream made a few appearances… So did bread. And during the holidays, I happily worked my way through a huge box of German Christmas treats - Lebkuchen, chocolate-covered pretzels, pralines - sent by a business associate from across the pond.

Not seeing glucose spikes in real time didn’t mean they weren’t happening.
But my priority was clear: restore weight first, worry about A1C later.

What happened next surprised me more than anything I’ve seen in years of health and biometrics tracking.

January 2026: A Stunning Surprise

I hadn’t worn a CGM since mid-2025. I hadn’t checked my A1C since October, when it was still sitting on the cusp. Now that I was close to my weight goal, I decided to put a CGM back on - fully expecting to see damage from five months of relaxed eating.

Instead, I was stunned.

On day one, my glucose stayed steady and low….didn’t peak over 130 mg/dL all day. I was suspicious the CGM was “off” since I expected to see the usual averages. I double-checked this with finger-prick tests - the CGM was accurate. Over the following days, my surprise escalated to something close to disbelief.

My insulin sensitivity had dramatically improved.

Today, my average glucose sits around 90 mg/dL:

• without restriction

• without fear

• without hyper-vigilance

• and without worrying about weight loss

I went from an average glucose of ~118 mg/dL in October to ~90 mg/dL in January.

A bowl of steel-cut oats — which would have spiked me to 170–180 mg/dL last year — now barely reaches 130 mg/dL. My morning glucose, once in the low 90s, is now typically in the low 70s.

What Changed?

Two things - and they likely matter together.

1. Saffron (Yes, Really)

I didn’t discover saffron through a paper or a podcast.

In October, while visiting Turkey, my husband and I wandered into a spice shop in the Grand Bazaar, in Istanbul. The shop owner enthusiastically explained saffron’s benefits - mood, inflammation, vitality - and then casually added:

“It’s a potent spice to regulate insulin.”

That phrase got my attention!

Given how close my A1C was to the prediabetic range, we figured: why not try it? We bought an 8-ounce bottle of saffron threads to take home.

We began drinking a simple daily “tea”:
10–12 saffron threads, steeped in hot (not boiling) water for 20 minutes.

No expectations. No protocol. Just curiosity….and I’d actually forgotten why we were even drinking it!!

2. C8 MCT Oil (The Quiet Enabler)

Around the same time (October 2025), there was one other change to my routine. I began adding one teaspoon of C8 MCT powder to the two cups of morning coffee I drink daily.

C8 doesn’t lower glucose directly. Instead, it provides rapid ketone fuel, reducing reliance on glucose and improving metabolic flexibility. In hindsight, it likely helped stabilize my baseline, flatten curves, and buffer glucose excursions - creating fertile ground for saffron’s effects to shine.

What I’m Seeing Now

Since adding saffron and MCT C8 powder, my glucose response has fundamentally shifted over the last few months - in a way I could only have dreamed of last year.

Foods that once guaranteed spikes - pasta, potatoes, bread, even a chocolate praline - now produce modest, well-contained responses, with faster recovery and smoother curves. Peaks generally stay under 130 mg/dL, often much lower depending on food and combination (order of eating).

Even more remarkable:

• My post-meal glucose reliably drops back under 100 mg/dL within ~90 minutes

• My fasting glucose is now typically in the low 70s

• Overnight glucose is flat and stable

• Overall variability is dramatically reduced

My glucose metabolism is no longer being managed into submission.
It’s doing what it’s supposed to do again. This is metabolic resilience and I’m delighted it found me entirely by chance in an Istanbul spice bazaar.

How Might Saffron Be Doing This?

• Improved insulin sensitivity
  Saffron’s bioactive compounds (notably crocin and safranal) appear to enhance GLUT4 translocation, improving glucose uptake in skeletal muscle.

• Reduced stress-mediated glucose release
  Saffron influences stress and cortisol signaling - critical, because stress alone can drive post-meal glucose elevations.

• β-cell protection
  Evidence suggests saffron reduces oxidative stress on pancreatic β-cells, potentially improving first-phase insulin response.

• Central glucose regulation
  Saffron also acts in the brain, influencing glucose sensing and appetite signaling - an often-overlooked layer of glucose control.

A Final Word

Everyone responds differently.
This is N=1

But I would be remiss not to share something that has been genuinely life-changing for me.

Maybe saffron is under-explored simply because of its cost in the U.S. I don’t know. What I do know is that I’ll be eternally grateful to a spice merchant in Istanbul who insisted I take some home.

When I put on a CGM a few weeks ago, I had almost forgotten about him - until I found myself scrambling for an explanation as to why my average glucose dropped so obviously and dramatically - despite breaking all my usual dietary rules for months!

Sometimes the biggest shifts come from the least expected places.

Nature is a beautiful thing and yes, plants can be the most effective medicine!

Disclaimer:
This is my personal, N=1 experience and not medical advice. Responses to saffron, C8 MCT oil, and dietary changes can vary significantly between individuals. Those with diabetes, reactive hypoglycemia, eating disorders, or who use glucose-lowering medications should consult a qualified healthcare professional before making changes.

That structure is lipids.

This topic has become central in my own efforts to silence the expression of my APOE4/4 genes, not by chasing single targets, but by supporting the structural foundation that everything else depends on.

Why Lipids Matter More Than They Get Credit For

Every cell in the body is enclosed by a phospholipid bilayer. Inside each cell, mitochondria - our energy engines - are also wrapped in highly specialized lipid membranes.

These membranes determine:

• how nutrients enter the cell

• how waste products leave

• how receptors respond to hormones and neurotransmitters

• how efficiently mitochondria produce ATP

• how much oxidative stress and inflammation accumulate

When membrane lipids are damaged, depleted, or replaced with inferior substitutes, cellular function degrades - even when standard lab values appear “normal.”

This is especially relevant for those of us with APOE4, a genotype known for inefficient cholesterol efflux. That reality naturally leads to a deeper question: what is actually controlling cholesterol movement at the cellular level?

Cholesterol Doesn’t Simply “Leave” a Cell

Cells don’t dump cholesterol into the bloodstream on their own.

Cholesterol exits cells through active export systems embedded in the cell membrane, primarily transporters such as ABCA1 and ABCG1. These transporters:

• sit within the lipid bilayer

• require a fluid, well-composed membrane to function

• load cholesterol onto lipid-poor particles such as HDL or ApoE

So cholesterol efflux isn’t just about how much cholesterol is inside a cell -
it’s also about the condition of the membrane it must pass through.

ABCA1: A Quiet but Critical Player in Alzheimer’s Risk

One of the lesser-discussed contributors to Alzheimer’s risk - particularly for APOE4 carriers - is ABCA1, a transport protein responsible for moving cholesterol out of cells and properly lipidating ApoE particles.

When ABCA1 function is suboptimal:

• cholesterol lingers inside neurons and glial cells

• membranes become stiffer

• ApoE (already less efficient in APOE4) becomes poorly lipidated and more inflammatory

Importantly, this is rarely an “on/off” genetic defect. It’s usually a matter of efficiency.

ABCA1 activity appears to be supported by:

• healthy membrane composition

• adequate phospholipid availability

• good mitochondrial function

• regular physical activity

• metabolic flexibility

• lower chronic inflammation

In other words, cholesterol trafficking is not just a lab-number issue - it’s structural and functional.

Why Membrane Composition Matters So Much

Cell membranes aren’t passive barriers. They are working surfaces.

Their ability to move cholesterol depends on:

• membrane fluidity

• proper phospholipid balance

• intact lipid raft structure

• healthy mitochondrial and ER membranes

If membranes become:

• rigid

• oxidized

• depleted of key phospholipids

then cholesterol export becomes inefficient even when transport proteins are present.

It’s like having delivery trucks waiting at a loading dock with no staff to unload. The system exists - but nothing moves smoothly.

Where APOE4 Complicates the Picture

APOE4 introduces several overlapping vulnerabilities:

1. Poor ApoE Lipidation

APOE4 forms less well-lipidated ApoE particles, meaning cholesterol has fewer high-quality carriers and lingers longer inside cells.

2. More Rigid, Cholesterol-Dense Membranes

APOE4 brains tend to show:

• higher membrane cholesterol content

• altered lipid raft structure

• reduced membrane fluidity

Rigid membranes translate into sluggish transporter function.

3. Structural Stress on ABCA1

ABCA1 does not operate in isolation. It depends on:

• adequate phosphatidylcholine

• sufficient plasmalogen content

• intact membrane curvature and flexibility

When membranes are phospholipid-poor or oxidatively damaged, ABCA1 efficiency drops - even if the gene itself is active.

Why This Matters Especially for the Brain

Neurons and glial cells:

• synthesize their own cholesterol

• rely heavily on local recycling and efflux

• tolerate cholesterol accumulation poorly

When efflux falters:

• synaptic membranes stiffen

• receptor signaling degrades

• inflammation rises

• amyloid processing shifts in an unfavorable direction

This helps explain why APOE4 brains can show pathology even without markedly elevated blood cholesterol. It’s a cellular trafficking problem, not simply a serum lipid issue.

Where Phospholipids and Plasmalogens Fit In

Without overreaching beyond the data, the logic is straightforward:

• Phosphatidylcholine provides structural material for ApoE and HDL particles

• Plasmalogens support membrane fluidity and antioxidant defense

• Healthier membranes improve transporter performance

• Better transporter performance improves cholesterol efflux

• Improved efflux reduces intracellular cholesterol stress in neurons

This doesn’t “fix” APOE4 - but it may well reduce one of its most important structural bottlenecks.

Where Dietary Fats Quietly Reinforce This Framework

Alongside targeted phospholipid support, I think it’s important not to overlook the quieter, foundational role of dietary fats that integrate into membranes over time. Extra virgin olive oil provides monounsaturated fats and polyphenols that support membrane fluidity while reducing oxidative stress within the lipid bilayer, particularly in neuronal and mitochondrial membranes. In parallel, supplemental omega-3s - with an emphasis on DHA - supply a fatty acid that is structurally essential for synaptic membranes, lipid rafts, and mitochondrial efficiency. DHA is not simply a signaling molecule; it is a literal building block of neuronal architecture. Taken consistently, these fats don’t replace Lipid Replacement Therapy, but they help ensure that when phospholipids and plasmalogens are supplied, they are incorporated into a membrane environment that is flexible, resilient, and less prone to inflammatory signaling.

Why Pulsing Lipid Support Makes Sense

Efflux systems don’t benefit from constant stimulation.
They benefit from repair, followed by time to function normally.

How I Personally Think About LRT (as APOE4/4)

I don’t use Lipid Replacement Therapy because I’m chasing perfection or trying to micromanage biology.

Because I’m APOE4/4, I know my brain depends heavily on healthy lipids — and I also know lipid handling isn’t always efficient or forgiving. My goal isn’t to push lipids constantly, but to ensure I’m not quietly missing important building blocks over time.

How I Use It, in Plain Terms

I use phosphatidylcholine as the base, specifically BodyBio PC, (*use code APOE4 for a discount) because it’s clean, gentle, and after using it for several years, I trust the brand!

I take it with meals, split across the day, without obsessing over dose. I’m simply supplying raw material during periods when I’m intentionally supporting membrane structure.

At times, I layer in plasmalogens, using Prodrome Glia and Prodrome Neuro. I think of these as more brain-specific lipids - especially relevant as plasmalogen levels decline with age and appear tied to Alzheimer’s risk.

I don’t take these continuously. I use / pulse them intentionally.

The Rhythm That Feels Right to Me

My pattern is simple:

• several weeks on (PC plus plasmalogens)

• several weeks off, with no lipid-specific supplementation

During the “on” phase, I support structure.
During the “off” phase, I let the system integrate and function.

That rhythm feels far more biologically appropriate than constant daily input.

One very simple, low-effort addition I rely on to support Lipid Replacement Therapy is eating small fatty fish - usually sardines or mackerel - about three times per week. I’ll be honest: sardines aren’t everyone’s favorite, so I often make them into patties, which makes them far more appealing without the fishy taste. I think of this as a practical safety net. Because DHA and EPA need to be incorporated into cell membranes over time, getting them regularly from whole food provides a buffer in case absorption from supplements is imperfect or inconsistent, especially in a genotype where lipid trafficking is already less efficient. Given how central membrane integrity is to mitochondrial function, lipid trafficking, and synaptic resilience, this is an easy, sustainable habit that quietly reinforces the goals of Lipid Replacement Therapy without requiring precision or perfection.

A note for sterol hyperabsorbers:

A subset of individuals - including some APOE4 carriers - are sterol hyperabsorbers, meaning they absorb plant sterols more efficiently through NPC1L1. In these cases, foods rich in phytosterols (such as nuts, seeds, and certain plant oils) can raise circulating plant sterols and potentially contribute to arterial or cellular sterol burden. This does not negate the importance of membrane integrity or lipid replacement, but it does mean that fat selection matters. For sterol hyperabsorbers, focusing on low-sterol fat sources while supporting phospholipids, DHA, and membrane structure can help align lipid replacement goals with individual absorption biology. There is one test I’m aware of that clearly identifies sterol absorption status: the Boston Heart Diagnostics Cholesterol Balance Test. It measures cholesterol production markers (desmosterol and lathosterol) alongside absorption markers (beta-sitosterol and campesterol). For many years I consumed large amounts of flaxseed, believing it was beneficial - only to later discover that I am a sterol hyperabsorber and need to avoid foods high in plant sterols. In that context, Ezetimibe (Zetia), which blocks intestinal sterol absorption, has been particularly helpful.

Where Statins Fit in a Lipid Replacement Framework

A brief note on statins is warranted here, because Lipid Replacement Therapy is often misunderstood as being “anti-statin.” That is not how I think about it. As I discussed in a previous postprimarily reduce circulating cholesterol synthesis and particle burden, while LRT focuses on restoring membrane composition, mitochondrial integrity, and lipid trafficking at the cellular level. These are not redundant targets. In an APOE4 context, lowering inflammatory lipid flux in the bloodstream and improving the quality and resilience of cellular membranes can be complementary strategies rather than competing ones. Linking the two helps move the conversation away from ideology and toward systems-level biology.

Final Thought

For me, Lipid Replacement Therapy is about respecting structure.

Healthy membranes don’t guarantee cognitive longevity - but without them, everything else has to work harder than it should. Pulsing phosphatidylcholine and plasmalogens feels like a reasonable, measured way to ensure my brain isn’t quietly short on the materials it depends on most.

Disclaimer

This content is for educational and informational purposes only and reflects my personal research, my interpretation of scientific literature, and my individual experience. It is not intended as medical advice, diagnosis, or treatment, and should not be used as a substitute for professional medical care.

Discussions of Lipid Replacement Therapy (LRT), phosphatidylcholine, plasmalogens, APOE genotype, cholesterol metabolism, ABCA1, or related mechanisms are theoretical and evolving. While grounded in current research, many concepts described are based on mechanistic reasoning, preclinical data, or limited human studies, and definitive clinical outcomes are not established.

It was clearly associated with Alzheimer’s disease, the strongest genetic risk factor we know, yet the why remained frustratingly vague. APOE4 was treated as probabilistic destiny rather than actionable biology. I carry it. I worried. I hoped answers would emerge before it was too late.

Across the last several years, and accelerating recently, a much clearer picture has emerged. Not from one dramatic study, but from converging lines of evidence that all point in the same direction:

APOE4 actively disrupts lipid trafficking and lipid metabolism in the brain.

And that disruption appears to sit upstream of inflammation, synaptic failure, amyloid accumulation, and tau pathology.

This is not semantics. It’s a fundamental shift in how Alzheimer’s risk is understood, and how it should be addressed.

What is now crystallizing across the science

Independently, multiple research groups studying astrocytes, microglia, neurons, lipid and mitochondrial metabolism have arrived at overlapping conclusions:

• APOE4 alters how lipids are transported between brain cells
• Support cells accumulate lipids instead of efficiently using or delivering them
• Fatty acids are stored in lipid droplets rather than oxidized
• Mitochondrial lipid metabolism becomes impaired
• Inflammatory signaling increases.
• Neurons lose access to the structural lipids they depend on

Critically, these changes appear early, well before cognitive symptoms, and they occur independent of amyloid plaques.

Amyloid and tau still matter. But they increasingly look like downstream accelerants, not the original failure.

The original failure appears to be metabolic and structural.

Why lipid trafficking matters so much

Neurons are unusually dependent cells.

They do not make their own cholesterol or phospholipids in meaningful amounts. They rely on astrocytes and microglia to deliver the lipids required for:

• synaptic membranes
• mitochondrial membranes
• myelin maintenance
• dendritic remodeling
• membrane repair

When lipid delivery falters, neurons don’t immediately die …. they degrade. Synapses weaken. Energy falters. Plasticity declines. Vulnerability increases.

From this perspective, Alzheimer’s looks less like a protein aggregation disorder and more like a chronic failure of cellular maintenance and lipid logistics.

APOE4 doesn’t merely increase risk, it changes how the system operates.

The only logical response: intervene upstream

If the core vulnerability is impaired lipid handling, then prevention cannot revolve solely around plaque clearance or late-stage rescue attempts.

The rational strategy becomes:

Support lipid transport
Protect membrane integrity
Improve lipid utilization
Reduce inflammatory lipid signaling
Preserve metabolic and circadian stability

This reframes prevention from fear-driven restriction to active systems support.

Share

How I’m responding practically, not theoretically

I am APOE4/4. I’m not interested in abstract reassurance. I want biological leverage.

1. Supporting membrane integrity deliberately

APOE4 delivers lipids poorly. That means membranes age faster.

I focus on rebuilding and maintaining membrane composition, particularly phospholipids critical for neuronal and mitochondrial health. It’s about structural maintenance.

2. Preventing toxic lipid accumulation

The problem is not fat, it’s fat that can’t be processed.

So, I prioritize:
• mitochondrial support
• fatty-acid utilization
• metabolic flexibility
• resistance training

When lipids are oxidized properly, they don’t accumulate pathologically in glial cells.

3. Stabilizing gut–brain lipid signaling

Peripheral inflammation worsens central lipid dysfunction.

I’ve focused on restoring gut barrier integrity and short-chain fatty acid signaling, not as a digestive project, but as neuroinflammatory control.

4. Protecting sleep as a biological process

Sleep is when the brain clears lipids and repairs membranes.

Fragmented sleep undermines lipid trafficking via the glymphatic system. I treat deep sleep as non-negotiable neuroprotection, not just “nice to have”.

5. Avoiding known APOE4 stressors

Some exposures matter more when lipid handling is fragile:

• chronic glucose volatility
• inflammatory overload
• sterol excess
• hormonal instability

Why this approach feels different

This approach is responding to what the research is clearly telling us.

When multiple independent fields converge on the same mechanism, the prudent move is not to wait for perfect consensus, it is to act intelligently on the emerging signal.

My Conclusion

APOE4 is not destiny, but it is instruction.

Research tells us where the system is fragile.
It tells us what appears to break first.
And increasingly, it points to ways, how to intervene.

By focusing on lipid trafficking, membrane integrity, and metabolic stability, we are no longer guessing. We are working with the biology instead of reacting to its failure.

That shift - from risk management to systems support - may be the most important evolution in Alzheimer’s prevention we’ve seen in decades.

And for those of us carrying APOE4, it finally gives us a plan. Stay tuned for my next post, which will discuss LRT … Lipid Replacement Therapy.

If you are new here: APOE status is determined primarily by two SNPs (genetic markers): rs429358 and rs7412. In most direct-to-consumer genetic reports, APOE4/4 corresponds to rs429358 C/C and rs7412 C/C.

Share

Senescent cells are cells that have exited the cell cycle but refuse to die. They are often referred to as “zombie cells”. Instead, they secrete a potent mix of inflammatory cytokines, proteases, and growth factors — the senescence-associated secretory phenotype (SASP) — which damages surrounding tissue and amplifies inflammation.

For APOE4 carriers, this matters disproportionately.

In the brain, senescent cells have been identified in astrocytes, microglia, endothelial cells, and oligodendrocyte lineage cells — precisely the cell types already vulnerable in APOE4 brains. These cells govern neuroinflammation, vascular integrity, metabolic support, and synaptic health, all of which tend to show earlier dysfunction in APOE4 carriers

Why APOE4 Requires a Different Strategy

APOE4 biology is characterized by:

• Higher baseline inflammation

• Chronically primed microglia

• Earlier blood–brain barrier vulnerability

• Greater sensitivity to immune, thyroid, and mitochondrial suppression

This means that strategies tolerated by the general population could backfire when applied continuously in APOE4 carriers.

Senolytics are a perfect example.

They are powerful tools — but they are not meant to be taken every day.

For APOE4 carriers, indiscriminate or continuous senolytic pressure risks disrupting immune surveillance, thyroid signaling, and mitochondrial resilience — systems that are already more fragile.

The Study That Changed the Alzheimer’s Conversation

One of the most influential studies in this field demonstrated that clearing senescent astrocytes and microglia in a tau mouse model reduced tau pathology and preserved cognitive function.

This does not prove human prevention. But it strongly suggests that senescent glial cells are active contributors to neurodegeneration rather than innocent bystanders — a finding with particular relevance for APOE4 brains that enter inflammatory and vascular stress states earlier.

My Experience With Potent Senolytics (and Why It Shaped My Approach)

Under the guidance of the late Dr. Alan Green, Dasatinib was discussed and prescribed for me as part of a senolytic strategy to follow. Despite extensive research prior to taking the first dose, and taking only half of the prescribed dose, I experienced significant side effects…. including a clear episode of tachycardia — unmistakable physiologic disruption along with significant nausea and strong headache.

It reinforced several truths:

• Dasatinib is a potent oncology drug, not a nutraceutical

• Individual sensitivity varies widely

• Even “low” doses can have systemic effects

• Strong Senolytics are not something to experiment with casually

To reduce side effects, I later broke the dose into smaller fractions (+/- 25 mg) staggered over the day in minimum 6 hour increments, maintaining exposure while avoiding excessive peak levels. Even so, the experience solidified my conviction: respect the biology, respect the drug, and err on the side of caution.

Why I Do Not Take Senolytics Daily

Senescent cells accumulate slowly. They do not require daily pressure.

Daily senolytics can:

• Blunt hormetic signaling

• Interfere with thyroid hormone transport

• Suppress immune surveillance

• Disrupt mitochondrial signaling

Instead, I follow the logic used in most animal models and early human studies:

Short pulses, followed by long recovery periods.

The Senolytics I Use

My core senolytics are:

• Quercetin

• Fisetin

  
  They target overlapping but not identical senescent cell populations, providing broader coverage without aggressive dosing.

• An additional 100 mg Dasatinib total, micro-dosed over 24-36 hours during pulse periods only, to extend coverage without increasing peak exposure

This micro-dose is never taken daily and never outside pulse windows.

My Annual APOE4/4 Senolytic Calendar

Monthly Maintenance Pulses (8× per year)

January · February · April · May · July · August · October · November

• Duration: 2 consecutive days

• Each day:

  • Quercetin: 1,000 mg

  • Fisetin: 1,000–1,500 mg

• Added micro-dose (first day only):

  • 100 mg Dasatinib total, split into 25 mg × 4 doses

  • Morning · Midday · Late afternoon · Early evening

  • I skip the Dasatinib bedtime dosing if I am experiencing any unpleasant side effects and take the next morning.

Purpose:
Maintenance clearance — preventing senescent immune and glial cells from re-establishing a chronically inflamed baseline. It’s worth noting that Quercetin and Fisetin are both fat soluble so need to be taken with fat.

Quarterly Deep Reset Pulses (3× per year)

March · June · September

• Duration: 4 consecutive days

• Each day:

  • Quercetin: 1,000 mg

  • Fisetin: 1,500–2,000 mg

• Same micro-dose:

  • 100 mg Dasatinib total over 24 hours, split into 4-5 increment doses

I do not increase beyond this.

Purpose:
Broader systemic and CNS-adjacent senescent clearance, particularly relevant for aging microglia and endothelium.

Mandatory Senolytic Rest Month

December

• No quercetin

• No fisetin

• No Dasatinib micro-dose

• No other senolytics or aggressive polyphenols

This rest period matters. It allows immune surveillance, hormetic signaling, thyroid transport, and mitochondrial pathways to fully reset.

Guardrails I Consider Non-Negotiable

• I never overlap senolytic pulses with rapamycin (minimum 4 days apart)

• I space senolytics several hours away from thyroid medication

• I avoid stacking additional polyphenols on pulse days

• I do not fast aggressively or perform intense HIIT during pulses

How I Know It’s Working

I don’t expect fireworks during pulse days. Benefits show up weeks later, not immediately.

What I watch:

• hs-CRP trends

• Sleep depth and HRV

• Cognitive clarity

• Subtle inflammation markers

Quiet, cumulative improvement beats dramatic short-term effects.

Final Thoughts

This is my personal protocol, shaped by:

• APOE4/4 biology

• Inflammation sensitivity

• Thyroid considerations

• Mitochondrial health

• Long-term sustainability

I believe senolytics should feel like spring cleaning, not daily housekeeping.

Disclaimer

This post is for educational purposes only and does not constitute medical advice. It’s what I do, and what I know works for my body! Dasatinib is a prescription medication with significant risks and should only be used under medical supervision.